Stockwinners Market Radar for May 16, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Scholar Rock announces 25% workforce reduction - As part of its Q1 earnings press release earlier this evening, the company stated: "Scholar Rock is focusing its expertise in inhibiting the activation of latent growth factors on completing the Phase 2 TOPAZ extension clinical trial and the Phase 3 SAPPHIRE clinical trial, both of which are evaluating the potential of apitegromab to address motor function impairments in patients with spinal muscular atrophy. The SRK-181 program for the treatment of patients with solid tumors showing primary resistance to anti-PD-(L)1 therapy remains a priority with strategic value. While investment in the existing scientific platform continues, the Company is narrowing the scope of discovery programs it expects to pursue. The Company today announced a restructuring of its business to prioritize and focus on its clinical stage assets resulting in a reduction to its workforce by approximately 25%, in addition to the curtailment of previously planned hiring. The reduction in operating expenses relates to general and administrative spend and research activities related to earlier stage programs. In conjunction with the pipeline prioritization, these changes are expected to extend the cash runway into the fourth quarter of 2023."

18:49 EDT Middleby CEO acquires 7,500 common shares - In a regulatory filing, Middleby CEO Timothy John Fitzgerald disclosed the purchase of 7,500 common shares of the company on May 12 at a price of $132.286 per share.

18:23 EDT Nucor CEO: C.H.I. Overhead Doors acquisition is a 'homerun' - In an interview on CNBC's Mad Money, Leon Topalian said the C.H.I. Overhead Doors acquisition is a "natural continuation" of the company's strategy. It will generate "huge opportunities" for shareholders long-term, he noted. The cash Nucor is generating is "incredible," and the company will return at least 40% of its net earnings to shareholders, he said. Steel demand in the U.S. remains incredibly strong, he added.

18:09 EDT Euronet CEO Brown sells 10,000 common shares - In a regulatory filing, Euronet Worldwide CEO and president Michael Brown disclosed the sale of 10,000 common shares of the company on May 12 at a price of $111.11 per share.

18:04 EDT Logitech proposes to increase annual dividend 10% - Logitech announced that the company's board of directors has approved a proposal for a Fiscal Year 2022 cash dividend, which, if approved by shareholders, would be a 10% annual increase per share versus last year's dividend, or approximately CHF 0.96 per share. This proposal will be voted on by Logitech's shareholders at the company's Annual General Meeting in September 2022.

17:47 EDT Euroseas exercises option to build two additional containerships - Euroseas announced that it has exercised its option to proceed with the construction of two additional eco design fuel efficient containerships. The vessels will have a carrying capacity of about 2,800 teu each and will be built at Hyundai Mipo Dockyard Co. in South Korea. The two newbuildings are scheduled to be delivered during the fourth quarter of 2024. The total consideration for these two newbuilding contracts is approximately $86M and will be financed with a combination of debt and equity. The vessels are sisterships of four other vessels ordered by Euroseas Ltd. in June 2021 and January; Euroseas Ltd. has also ordered, and previously announced, three 1,800 teu vessels at the same shipyard. The company also announced that it intends to upgrade the engines of all of its six 2,800 teu vessels ordered to Tier III type and have the ships be LNG-ready where possible for a total incremental cost for all vessels of about $11M. Tier III type engine achieve lower NOx emissions. The three 1,800 teu vessels were ordered with Tier III type engines and are LNG-ready.

17:42 EDT David Einhorn's Greenlight adds Southwestern, exits Sonos in Q1 - David Einhorn's Greenlight Capital disclosed in an SEC filing its holdings as of March 31, 2022. The fund's seven new buys during the first quarter included, by size of position, Southwestern Energy (SWN), Weatherford International (WFRD), International Seaways (INSW), TD Synnex (SNX), and Energy Select Sector SPDR Fund (XLE). Greenlight exited 11 positions during the quarter, including by size of previous position Jack in the Box (JACK), Sonos (SONO), Twitter (TWTR), Concentrix (CNXC), and Freyr Battery (FREY). The fund increased its stake in 12 holdings, including by size of previous position Kyndryl (KD), SPDR Gold Shares (GLD), Civitas Resources (CIVI), Chemours (CC), and LivaNova (LIVN). Greenlight reduced its stake in 16 holdings, including by size of previous position Green Brick Partners (GRBK), Capri Holdings (CPRI), Brighthouse Financial (BHF), GoPro (GPRO), and Victoria's Secret (VSCO). The fund's top holdings as of March 31, in order of size, were Green Brick, Brighthouse, Teck Resources (TECK), Change Healthcare (CHNG), and Atlas Air Worldwide (AAWW).

17:34 EDT Jana Partners exits Macy's, cuts LabCorp in Q1 - Jana Partners disclosed in an SEC filing its holdings as of March 31, 2022. The fund exited two positions during the first quarter, including by size of previous position Macy's (M) and LivePerson (LPSN). Jana increased its stake in one holding, namely Zendesk (ZEN). The fund reduced its stake in five holdings, including by size of previous position TreeHouse (THS), LabCorp (LH), SPDR S&P 500 ETF Trust (SPY), Encompass Health (EHC), and Mercury Systems (MRCY). Jana's top holdings as of March 31, in order of size, were Zendesk, Conagra (CAG), Mercury Systems, Encompass Health, and TreeHouse.

17:31 EDT Gulf Coast Express Pipeline announces open season for expansion project - Gulf Coast Express Pipeline announced an open season to solicit commitments for an expansion project on its system. Upon achieving a final investment decision, the project will increase GCX's capacity by nearly 570 million cubic feet per day. The project will involve primarily compression expansions on the GCX system to increase natural gas deliveries from the Permian Basin to South Texas markets. Pending customer commitments, the target in-service date for the project is December 1, 2023. The open season begins May 16, 2022, and ends June 6, 2022, at 5 p.m. Central Time, though GCX reserves the right to extend the open season as needed. GCX is jointly owned by subsidiaries of Kinder Morgan, Inc. (KMI), DCP Midstream, LP (DCP), an affiliate of ArcLight Capital Partners, LLC, and Kinetik Holdings Inc. (KNTK) with an ownership interest of 34%, 25%, 25% and 16% respectively. Kinder Morgan Texas Pipeline is the operator of GCX.

17:29 EDT Priority Technology board authorizes share buyback for up to $10M

17:18 EDT Third Point lowers stakes in Amazon, Intuit, exits Alphabet position - Third Point LLC disclosed in an SEC filing its holdings as of March 31, 2022. Third Point's nine new buys during the first quarter included, by size of position, CSX (CSX), Alcoa (AA), Ovintiv (OVV), Suncor (SU), and Mosaic (MOS). Third Point exited 25 positions during the quarter, including by size of previous position, Alphabet (GOOGL), Upstart (UPST), Accenture (ACN), CoStar (CSGP), and Burlington Stores (BURL). Third Point increased its stake in six holdings, including by size of previous position, SentinelOne (S), EQT (EQT), Zendesk (ZEN), Hertz (HTZ), and DuPont (DD). Third Point reduced its stake in 20 holdings, including by size of previous position, Amazon (AMZN), Intuit (INTU), Microsoft (MSFT), Rivian (RIVN), and Danaher (DHR). Third Point's top holdings as of March 31, in order of size, were SentinelOne, PG&E (PCG), Danaher, S&P Global, and Intuit.

17:16 EDT Aerovate Therapeutics presents phase 1 data for AV-101 - Aerovate Therapeutics "presents Phase 1 results at the American Thoracic Society International Conference in San Francisco. Aerovate's data show that AV-101, a novel inhaled dry powder formulation of imatinib, was generally well-tolerated by healthy adult volunteers with no serious adverse events reported. Imatinib previously demonstrated a statistically significant and clinically meaningful benefit in PAH patients in the global Phase 3 IMPRES trial, conducted by Novartis, when administered orally as a tablet but was poorly tolerated due to adverse events. The development of oral imatinib for PAH was discontinued. Aerovate designed AV-101, a dry powder inhaled formulation of imatinib, to target imatinib's anti-proliferative activity in the pulmonary vasculature by direct delivery to the lungs while potentially avoiding the treatment-limiting systemic toxicities seen with oral imatinib."

17:04 EDT Valens CEO Tyler Robson steps down as chair, Andrew Cockwell succeeds - Valens announced that it has separated the roles of chair and CEO and appointed Andrew Cockwell as its new chair of the board, effective immediately. This decision follows the company's recent Nasdaq listing and its commitment to governance best practices including transparency and accountability. Tyler Robson has stepped down as chair in full support of this decision and will remain on the board and as the CEO of the company.

16:52 EDT Ortho Clinical Diagnostics shareholders vote to approve Quidel combination - Ortho Clinical Diagnostics (OCDX) announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the company with Quidel Corporation (QDEL) pursuant to the business combination agreement, dated December 22, by and among the company, Quidel, and the other parties thereto. The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and Wales and satisfaction of other closing conditions and is expected to occur on May 27.

16:50 EDT Athira Pharma continues to urge shareholders to vote for its director nominees - Athira Pharma issued the following statement in response to Richard A. Kayne's suspension of his proxy contest: "We appreciate the strong support of our shareholders throughout this process and their recognition of the incredible talent and commitment of the people across Athira. We continue to urge shareholders to vote "FOR" Athira's three director nominees on the WHITE proxy card. The Athira board is highly qualified and actively engaged in the development and execution of Athira's strategy. It has been purpose-built for this phase in the company's evolution. We have the right strategy, as well as the right leadership team and board of directors, to drive Athira's success. As we enter a pivotal chapter, with topline results from the Phase 2 ACT-AD study expected by the end of the second quarter of 2022 and multiple other upcoming clinical milestones, the company will remain focused on doing what is right for Athira, our shareholders, and our patients and their caregivers. We look forward to an ongoing dialogue with our shareholders as we execute our strategy. Athira's board urges shareholders to vote today "FOR" Athira's three director nominees - Joseph Edelman, John M. Fluke, Jr. and Grant Pickering - on the WHITE proxy card."

16:46 EDT Hayward names John Collins chief supply chain officer - Hayward Holdings announced the appointment of John Collins as Senior Vice President and Chief Supply Chain Officer, effective May 16, 2022, in conjunction with Don Smith's planned retirement from the Company. Collins will oversee all integrated supply chain activities across the Company's global enterprise, including manufacturing, distribution, sourcing, materials management, quality, and environment, health and safety. In this role, Collins will continue to build on Hayward's long-term vision and strategy for a world-class end-to-end supply chain function and will focus on driving operational effectiveness and continuous improvement. Collins will report to Hayward's CEO Kevin Holleran and be based out of the Company's new corporate headquarters in Charlotte, N.C. The location will give Collins easy access to Hayward's largest manufacturing facility in Clemmons, N.C. and new distribution center in Mocksville, N.C.

16:39 EDT Sportsman's Warehouse appoints Sruti Patnaik as chief information officer - Sportsman's Warehouse (SPWH) announced the appointment of Sruti Patnaik as their new chief information officer. She will be responsible for leading the company's Information Technology efforts and further building out it's omni-channel capabilities. Patnaik brings more than 20 years of retail experience as a senior executive with Ross Stores (ROST). Most recently, she was a senior VP and IT executive over supply chain, stores, corporate applications and QA services.

16:38 EDT First Solar to sell Japan assets to PAG Real Assets - First Solar announced that it has entered into definitive agreements with funds managed by PAG Real Assets, pursuant to which PAG will acquire from First Solar its 293 megawatts DC utility-scale solar project development platform, and a solar operations and maintenance platform with approximately 665 MWDC under management, in Japan. The transaction is expected to close in the second quarter of 2022 for the project development platform and the second half of 2022 for the O&M platform, in each case after obtaining regulatory approvals, the receipt of third-party consents and satisfying other customary closing conditions.

16:36 EDT WillScot Mobile Mini acquires Elite Modular Leasing and Sales - WillScot Mobile Mini Holdings Corp. announced that it has acquired Elite Modular Leasing and Sales, Inc. The transaction was funded with cash on hand and borrowings under the company's revolving credit agreement. This acquisition adds approximately 900 modular units to the company's existing operations throughout California.

16:35 EDT Abbott announces efforts to support formula supply since recall - Since the recall, the company has taken numerous measures to mitigate the supply shortage. Specifically, it has focused on production in its Cootehill, Ireland, facility to serve state Special Supplemental Nutrition Program for Women, Infants and Children consumers. Abbott has been working with the U.S. Department of Agriculture and WIC agencies and paying rebates on competitive products in states where Abbott holds the WIC contract, when Similac is not available. Abbott said Friday it will continue to pay rebates for competitive products through August 31. This means program participants will continue to be able to obtain formula free of charge, whether it is Similac or formula from another manufacturer. Additionally, the company has: Air shipped millions of cans of infant formula powder into the U.S. from our FDA-registered facility in Cootehill, Ireland. Prioritized infant formula production at our Columbus, Ohio, facility, converting other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed and ramped production at our other U.S. manufacturing site in Casa Grande, Arizona, for powder infant formula. Offered an increased number and value of coupons available for all infant formula products, including Similac liquid ready-to-feed, to enable customers to purchase formula, either free or deeply discounted. Been running other facilities at full capacity to help replenish the supply in the market.

16:33 EDT Mirati Therapeutics appoints Laurie Stelzer as CFO - Mirati Therapeutics (MRTX) the appointment of Laurie Stelzer as the Company's CFO effective May 16. Laurie will report to the Company's CEO, David Meek. Laurie joins the Company most recently from Arena Pharmaceuticals, acquired by Pfizer (PFE), where she served as Executive Vice President and CFO since 2020. She brings 25 years of biopharma industry experience to her role in leading the company's finance functions. Prior to joining Arena, Laurie was the CFO at Halozyme Therapeutics where she led the finance, information technology, business development, project management and site operations organizations. Prior to joining Halozyme, Laurie held senior management roles at Shire, acquired by Takeda (TAK), including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. Previously she held positions of increasing responsibility during her fifteen-year career at Amgen, spanning the areas of finance, treasury, global accounting, and international/emerging markets.

16:32 EDT Corporacion America Airport reports April passenger traffic up 202.1% y/y - Corporacion America Airports S.A. reported a 202.1% YoY increase in passenger traffic in April 2022, reaching 73.5% of pre-pandemic levels of April 2019. Total passenger traffic in April 2022 grew 202.1% compared to the same month of last year, driven by increases across all countries of operations, particularly in Brazil, Italy and Argentina, where traffic demand continued to recover, following the full re-opening of borders on November 1, 2021 and the lifting of travel restrictions. Overall passenger traffic recovered to 73.5% of April 2019 levels, from 68.6% in March. International and domestic passenger traffic improved sequentially reaching 68.9% and 79.1% of pre-pandemic levels of April 2019, respectively.

16:30 EDT RenaissanceRe announces renewal of share repurchase program - RenaissanceRe Board of Directors approved a renewal of RenaissanceRe's authorized share repurchase program, bringing the total current authorization up to $500.0 million, which includes the remaining amounts under prior authorizations. The program will expire when the Company has repurchased the full value of the shares authorized, unless terminated earlier by the Board of Directors. Pursuant to the program, RenaissanceRe may repurchase shares through open market purchases and privately negotiated transactions, and the decision to repurchase common shares will depend on, among other things, the market price of the common shares and the Company's capital requirements.

16:26 EDT Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of March 31, 2022. Lone Pine made eight new buys during Q1, including by size of position, TSMC (TSM), Meta Platforms (FB), Atlassian (TEAM), Dick's Sporting Goods (DKS), Bill.com (BILL) and Thermo Fisher (TMO). The fund exited eight positions during the quarter, including by size of previous position, KE Holdings (BEKE), Adobe (ADBE), Snowflake (SNOW), NetEase (NTES), Confluent (CFLT) and PVH Corp. (PVH). Lone Pine Capital increased its stake in three holdings: Block (SQ), Microsoft (MSFT) and RH (RH). Lone Pine Capital reduced its stake in 15 holdings, including by size of previous position, Shopify (SHOP), Snap (SNAP), MasterCard (MA), UnitedHealth (UNH), DoorDash (DASH) and Bath & Body Works (BBWI). Lone Pine Capital's top holdings as of March 31, in order of size, were Microsoft, Amazon, Workday, ServiceNow and Bath & Body Works.

16:25 EDT Crispr Therapeutics appoints Morrow as CMO - CRISPR Therapeutics (CRSP) announced the appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer, CMO, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership experience in global drug development and joins CRISPR Therapeutics to lead the Company's global clinical development and regulatory operations. Dr. Morrow most recently served as Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone at Amgen (AMGN).

16:21 EDT Edenbrook says offer to take Hemisphere Media private 'unfair' to shareholders - Edenbrook Capital, one of the largest public shareholders of Hemisphere Media Group, with ownership of approximately 14.94% of the publicly traded A shares and 7.65% of the total company, including the privately held, super-voting B shares, announced that it has delivered the following letter to the Hemisphere Board of Directors. The letter stated, in part, "Our firm, Edenbrook Capital, LLC, is a large shareholder of Hemisphere Media Group, with ownership of approximately 14.94% of the publicly traded A shares and 7.65% of the total company, including the privately held, super-voting B shares. We have been patient, supportive shareholders for nine years, and in that time, we have enjoyed a collaborative, productive relationship with the company. But following last week's surprise announcement of a proposed transaction for the company to be taken private by insiders at a price that significantly undervalues the company, we feel compelled to share our views publicly for the benefit of all shareholders. In short, we believe this transaction is unfair to public shareholders as it undervalues the company and allows insiders to disproportionately benefit from the very share price erosion they are responsible for. In our view, a deal to take the company private at anything less than $12.00 per share is indefensible and would raise serious questions about the process, motivations and conflicts of interest surrounding the Insider Takeover."

16:20 EDT AMN Healthcare acquires Connetics USA, terms not disclosed - AMN Healthcare has acquired Connetics USA, an international nurse and allied recruitment company that specializes in nursing and allied professional direct hire recruitment and placements. Connetics USA helps healthcare professional candidates through the immigration and licensure processes to their arrival in the United States. The company serves clients across the United States, including hospitals, dialysis facilities, long-term care facilities. "We are thrilled to have the Connetics USA team join the AMN Healthcare family and to expand our ability to serve clients across the country at such a critical time," said AMN Healthcare Chief Executive Officer Susan Salka. "The number one challenge facing healthcare organizations today is the growing shortage of healthcare professionals, which is expected to continue for several years. International staffing and recruitment solutions are an increasingly important response to this issue, and Connetics USA will help us bring more qualified and experienced international professionals to the United States."

16:19 EDT UGI, MBL Bioenergy to fully fund South Dakota RNG projects - UGI Energy Services announced an agreement with MBL Bioenergy to fully fund the first set of renewable natural gas projects currently under development in South Dakota. In total, the project will represent over $70M of investment by MBL Bioenergy, of which 100% of the funds will be provided by UGIES. MBL Bioenergy is a joint venture partnership between UGIES, Sevana Bioenergy and a subsidiary of California Bioenergy with the sole purpose of developing RNG projects in South Dakota. The first set of projects, known as a cluster, will be built at three farms located north of Sioux Falls, SD, and is expected to generate approximately 300 million cubic feet of RNG annually once completed in calendar year 2024. Dairy waste from the farms will be anaerobically digested and then piped to a central upgrading facility before it is delivered into the interstate natural gas system near Dell Rapids, SD. UGIES, through its wholly-owned subsidiary, GHI Energy, will be the exclusive marketer for MBL Bioenergy. "This project sets a new standard for UGI in terms of scope and size and represents a huge milestone in UGI's investments in, and expected earnings contribution from, RNG projects," said Robert F. Beard, Executive Vice President - Natural Gas, Global Engineering, Construction & Procurement, UGI. "We are pleased to be partnering with industry-leading developers on this project that will substantially reduce greenhouse gas emissions, using dairy RNG as a vehicle fuel. We look forward to making additional investments in our MBL partnership as we advance the use of RNG as an environmentally responsible and clean energy solution."

16:18 EDT Veracyte says new data shows Percepta test accurately assesses lung cancer risk - Veracyte announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force screening criteria. The findings were presented today at the American Thoracic Society 2022 International Conference, being held in San Francisco. "Our analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk," said Carla R. Lamb, M.D., a pulmonary and critical care physician and Director of Interventional Pulmonary at Lahey Hospital & Medical Center who presented the study findings. "These findings suggest that the test can be reliably used in ever-smokers whose lung nodules were found incidentally, as well as through screening." For the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 met USPSTF screening criteria, while 78 did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier's sensitivity and specificity between the two groups. Specifically, among those who met the USPSTF criteria for lung cancer screening, the test's sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test's sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk.

16:17 EDT Shapeways names Andrew Nied as COO - Shapeways "announced the appointment of Andrew Nied as chief operating officer of the Company, effective May 16, 2022. In this role, Nied reports to Shapeways' Chief Executive Officer, Greg Kress, and is responsible for overseeing Shapeways' operations and growth initiatives. Prior to joining the Company, Mr. Nied served as chief supply chain officer of Gooten, a print on demand platform, from September 2020 to May 2022. "

16:14 EDT Gilead says FDA lifts clinical hold on investigational lenacapavir - Bilead Sciences announced the U.S. Food and Drug Administration has lifted the clinical hold placed on the company's Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical hold following the agency's review of Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Following today's decision from the FDA, all activity can resume in the clinical studies evaluating injectable lenacapavir for HIV treatment and HIV PrEP. During the clinical hold, screening and enrollment of study participants and the dosing of injectable lenacapavir were not permitted across all lenacapavir studies. Other study activities, including the monitoring of participants, the dosing of participants in comparator arms, and the dosing of oral formulations of lenacapavir continued according to the relevant study protocol. Gilead will now work with study site investigators to fully resume the lenacapavir clinical development programs as quickly as possible.

16:13 EDT Heron Therapeutics presents data from phase 2 study of ZYRNELEF - Heron Therapeutics presented at the Society for Obstetric Anesthesia and Perinatology, or SOAP, 54th Annual Meeting results from a Phase 2 open-label, multi-cohort study evaluating interim safety and efficacy of ZYRNELEF, or bupivacaine and meloxicam, extended-release solution administered postpartum to women undergoing a planned Caesarean section. ZYNRELEF is currently approved by the FDA for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. The primary objective of this 25-patient study was to characterize the pharmacokinetics (PK) of the active ingredients and excipients of ZYNRELEF in breast milk and/or plasma following postpartum administration of ZYNRELEF 300 mg/9 mg in Cohort 1 and 400 mg/12 mg in Cohort 2 to women undergoing a planned C-section who did not intend to breastfeed. Overall, a single postpartum dose of ZYNRELEF resulted in very low (microgram) levels of bupivacaine and meloxicam in breast milk. Levels of the well-known excipient dimethyl sulfoxide (DMSO) were barely detectable by 48 hours. The secondary objective was to assess the safety of ZYNRELEF and an exploratory objective was to characterize its efficacy in women undergoing C-section. Results from the study indicate that ZYNRELEF was well-tolerated across both the 300 mg/9 mg and 400 mg/12 mg doses tested. The data also suggest that ZYNRELEF 400 mg/12 mg may effectively manage postpartum pain and minimize postoperative opioid use

16:11 EDT Sunlight Financial authorizes up to $50M share buyback - On May 16, 2022, Sunlight's Board of Directors authorized a share repurchase program pursuant to which Sunlight may repurchase up to $50 million of Sunlight's Class A common stock over an 18-month period from the date of authorization. The purpose of the share repurchase program is to maximize long-term shareholder return through efficient allocation of capital. Sunlight intends to fund the share repurchases through a combination of cash on hand and future cash flow from operations. Under the share repurchase program, Sunlight may purchase common stock in open market transactions, block or privately-negotiated transactions, and may from time to time purchase shares pursuant to a trading plan in accordance with Rule 10b5-1 and Rule 10b-18 under the Exchange Act or by any combination of such methods, in each case subject to compliance with all Securities and Exchange Commission rules and other legal requirements.

16:07 EDT F45 Training reports Q1 SSS up 6% globally, 40% in the U.S.

15:08 EDT New Jersey reports April gaming revenue up 20% to $422.5M - Total gaming revenue reported by casinos, racetracks and their partners was $422.5M for April, reflecting a 20% increase from $352.2M reported in April 2021. For year-to-date, total gaming revenue reported by casinos, racetracks, and their partners was $1.6B reflecting a 19% increase from $1.35B reported in the prior period. Sports wagering gross revenue reported by casinos, racetracks, and their partners was $50.3M for April, reflecting an 8.2% decrease when compared to $54.8M in the prior period. Sports wagering gross revenue reported by casinos, racetracks, and their partners was $207.8M for the year-to-date, reflecting a 14.9% decline when compared to $244.2M for the prior period. For the month of April, internet gaming win reported by casinos and their partners was $136.9M, reflecting growth of 27% compared to $107.7M for the prior period. For the year-to-date period, internet gaming win reported by casinos and their partners was $545.4M, reflecting growth of 30.2% compared to $419M for the prior year-to-date period. Based upon filings with the Division of Gaming Enforcement, total casino win for the nine casino hotel properties was $235.3M for April, reflecting growth of 24.1% compared to $189.6M for April 2021. Year-to-date total casino win for the nine casino hotel properties was $848M, reflecting growth of 24.2% compared to $682.7 million for the prior period. Publicly traded companies in the space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

14:22 EDT Tiger Global buys Starry, exits Adobe in Q1 - Chase Coleman's Tiger Global disclosed in an SEC filing its holdings as of March 31, 2022. The fund's two new buys during the first quarter included, by size of position, Starry Group (STRY) and Dave Inc (DAVE). Tiger exited 83 positions during the quarter, including by size of previous position Netflix (NFLX), Adobe (ADBE), Coupa Software (COUP), Sunrun (RUN), and PayPal (PYPL). The fund increased its stake in 21 holdings, including by size of previous position CrowdStrike (CRWD), Li Auto (LI), Monday.com (MNDY), Block (SQ), and Kanzhun (BZ). Tiger reduced its stake in 46 holdings, including by size of previous position Zoom Video (ZM), Meta Platforms (FB), DoorDash (DASH), Uber (UBER), and Amazon (AMZN). The fund's top holdings as of March 31, in order of size, were Microsoft (MSFT), CrowdStrike, Nu Holdings (NU), Sea Ltd. (SE), and Snowflake (SNOW).

14:00 EDT KULR Technology Group trading resumes

13:42 EDT ISS recommends McDonald's shareholders vote for all director nominees - McDonald's Corporation announced that Institutional Shareholder Services has recommended that McDonald's shareholders vote on the WHITE proxy card FOR ALL of McDonald's director nominees in connection with the Company's 2022 Annual Shareholders' Meeting, scheduled to be held on May 26, 2022, at 9:00 a.m. CT. Accordingly, the McDonald's Board of Directors urges shareholders to vote FOR ALL of McDonald's director nominees on the WHITE proxy card and to disregard any materials, including any gold proxy card, that may be sent by the Icahn Group. In its report sent to clients on May 16, 2022, ISS stated: "On balance, the dissident campaign has not made a sufficient case, on an issue-specific or broader view of ESG, that the immediate replacement of incumbent directors is necessary at this time.... the prevailing scientific evidence [regarding sow welfare], along with the realities of commercial-scale agriculture, seem to suggest that there is a reasonable basis for the view espoused by [McDonald's] board....we are hesitant to support a proxy contest predicated on ESG issues in instances where the dissident is economically divorced from the potential impact of its proposals on the company's financial performance....In assessing this campaign, shareholders may want to consider that the board, which has overseen strong performance since the pandemic, is also dealing with developments in Ukraine, which have had a material impact on the company."

13:40 EDT 2U trading resumes

13:35 EDT Chegg trading halted, volatility trading pause

13:08 EDT Farmers & Merchants Bancorp raises mid-year dividend 4.7% to $7.85 per share - The Board of Directors of Farmers & Merchants Bancorp declared a mid-year cash dividend of $7.85 per share, an increase of 4.7% over the $7.50 per share paid in July of 2021. The cash dividend is payable on July 1, 2022, to shareholders of record on June 10, 2022

13:01 EDT Tonix Pharmaceuticals announces 1-for 32 reverse stock split - Tonix Pharmaceuticals Holding announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 17, 2022. The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. Tonix's common stock will continue to trade on the NASDAQ Capital Market under the symbol "TNXP" and under a new CUSIP number, 890260862. As a result of the reverse stock split, every thirty-two pre-split shares of common stock outstanding will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common stock from 1,600 million to 50 million shares. The reverse split will also apply to common stock issuable upon the exercise of Tonix's outstanding warrants and stock options.

12:46 EDT Commercial Vehicle Group down 4% to $6.37 after WSJ report of Rivian suit

12:26 EDT Lockheed-Raytheon JV awarded $309M in Javelin contracts from U.S. Army - The U.S. Army recently awarded the Javelin Joint Venture two production contracts for Javelin missiles and associated equipment and services with total value of $309. These contracts include more than 1300 Javelin missiles funded from the recent Ukraine Supplemental Appropriations Act and orders for several international customers including Norway, Albania, Latvia and Thailand. Javelin is developed and produced by the Javelin Joint Venture, a partnership of Raytheon Missiles & Defense (RTX) and Lockheed Martin (LMT). "The Javelin Joint Venture is working hard to meet this increase in demand," says Dave Pantano, Javelin Joint Venture vice president and Lockheed Martin Javelin program director. "Javelin's unique capabilities have proven to be a difference-maker in our users' defining moments, and we look forward to continuing our partnership with the Army to deliver this critical weapon system."

12:01 EDT Cloudflare falls -10.0% - Cloudflare is down -10.0%, or -$6.62 to $59.76.

12:01 EDT Nu Holdings falls -15.5% - Nu Holdings is down -15.5%, or -74c to $4.08.

12:00 EDT Sonendo rises 19.6% - Sonendo is up 19.6%, or 51c to $3.11.

11:50 EDT Ubisoft+ subscription service coming to PlayStation - Ubisoft (UBSFY) said that Ubisoft+ will come to PlayStation (SONY) in the future, bringing access to more than 100 titles, additional content packs, and rewards to the platform. The subscription service is currently available on PC, Stadia (GOOG), and Amazon Luna (AMZN), offering players day-one releases, classic games, and premium editions, and ultimately will be available on PlayStation and Xbox (MSFT). Ubisoft also revealed that beginning May 24, it will launch a new Ubisoft+ subscription for PlayStation Plus called Ubisoft+ Classics. Ubisoft+ Classics on PlayStation is a curated selection of popular games, including top-selling Assassin's Creed Valhalla, The Division, and For Honor, as well as beloved classic games like Child of Light, Far Cry 3 Blood Dragon, Watch Dogs, Werewolves Within, and more. Reference Link

11:35 EDT Silence Therapeutics PLC (ADS) trading halted, volatility trading pause

11:32 EDT Xerox awarded $164M contract by USDA to streamline practices - The U.S. Department of Agriculture has awarded Xerox a 10-year, $164M contract for continued Managed Print Services, new Electronic Fax Services and additional innovation across its agencies. The contract includes a total of up to 16,000 Xerox ConnectKey devices, with a large number of new devices across 3,500+ offices supporting over 100,000 employees. Using Xerox's technology and innovative solutions, the USDA will cultivate best practices in print management, increase file security, create customized initiatives for Federal 508 compliance and better support its mobile workforce. This partnership helps the USDA cut costs while providing integrated managed print services and EFS, using Xerox's customized web portal designed to manage both services cohesively.

11:24 EDT Accolade signs third-year renewal contract with TRICARE - Accolade CFO Steve Barnes said at Needham Technology and Media Conference that the company has signed the third-year renewal contract with TRICARE. "We had some uncertainty about a government contract getting our three-year contract signed up but we have since signed that up and that's in play for fiscal '23," the executive said. "It's a three-year pilot to demonstrate the value of our services and because it's a government contract, we sign the three-year contract upfront and it requires the renewal on each year of the contract. We have now renewed that contract for the third year. It's a bit of reduced fee for the third year than prior."

11:04 EDT Glass Lewis recommends Aerojet stockholders vote for special meeting request - Eileen Drake and the other members of the Committee For Aerojet Rocketdyne Shareholders and Value Maximizationy announced that Glass, Lewis & Co. has recommended that stockholders consent to the request of special meeting of stockholders sought by the Committee. In supporting Ms. Drake's and the Committee's solicitation to call a special meeting, Glass Lewis concluded: "...adequate information already exists to suggest the Lichtenstein Parties have taken something of an overly malleable approach to the "right" annual meeting date for shareholders...We believe this pliable procession, on its own, arguably already establishes a foundational case for intervention...Just as problematic ... is the fact that Mr. Lichtenstein's communique seems to imply pushing the annual meeting out to mid-July should be viewed as something of a nominal inconvenience to the shareholder franchise...We find this to be a disconcertingly relaxed approach to securing a clear shareholder mandate, given a battery of existing AGM delays, hampered executive effectiveness and the continued presence of a progress-stifling board deadlock...In short, we do not consider Mr. Lichtenstein's more recent case against calling a special meeting finds meaningful purchase....Given the sum of available information, including what seems to be ARD's tenuously fixed meeting date, the inability of the current board to efficiently and effectively represent the interests of ARD's unaffiliated investors and what we consider to be comparatively limited risk associated with setting a firm backstop on a process that has pushed ARD well beyond its typical annual meeting date, we believe there is adequate cause for investors to support the current solicitation at this time."

10:49 EDT Huadi International Group Company Ltd trading resumes

10:35 EDT Trump 'generally obligated' to give TruthSocial six hour head start - Digital World Acquisition Corp. (DWAC) disclosed this morning a proxy statement relating to its proposed merger with Trump Media & Technology Group, which it refers to TMTG. Digital World stated, "President Trump is generally obligated to make any social media post on TruthSocial and may not make the same post on another social media site for 6 hours. Thereafter, he is free to post on any site to which he has access. Thus, TMTG has limited time to benefit from his posts and followers may not find it compelling to use TruthSocial to read his posts that quickly. In addition, he may make a post from a personal account related to political messaging, political fundraising or get-out-the-vote efforts on any social media site at any time." Donald Trump is currently banned from Twitter (TWTR) but Elon Musk, who is seeking to acquire the company, has come out against the ban. Shares of Digital World Acquisition are up 6%, or $2.40, to $44.38 in morning trading.

10:00 EDT Forge Global falls -6.9% - Forge Global is down -6.9%, or -$1.93 to $26.16.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -12.9% - ProShares UltraShort Bloomberg Natural Gas is down -12.9%, or -92c to $6.19.

10:00 EDT WideOpenWest rises 12.4% - WideOpenWest is up 12.4%, or $2.30 to $20.79.

09:58 EDT Twilio names Joyce Kim as chief marketing officer - Twilio announced Joyce Kim will be joining the company as Chief Marketing Officer, reporting to President of Revenue, Elena Donio. As Chief Marketing Officer, Kim will lead global marketing as the company executes its vision of becoming the leader in the emerging customer engagement category, Twilio said in a statement. Joyce Kim joins Twilio from Genesys, where she also served as Chief Marketing Officer and was responsible for driving market expansion and enterprise revenue growth.

09:52 EDT Griffon trading resumes

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -12.7% - ProShares UltraShort Bloomberg Natural Gas is down -12.7%, or -90c to $6.21.

09:47 EDT Carvana rises 10.2% - Carvana is up 10.2%, or $3.89 to $42.20.

09:47 EDT WideOpenWest rises 14.9% - WideOpenWest is up 14.9%, or $2.75 to $21.24.

09:40 EDT Cushman & Wakefield. Greystone close sale, financing of Hoover property - The joint venture team of Cushman & Wakefield and Greystone announced that they arranged the sale of and provided acquisition financing for City Heights Hoover, a 160-unit multifamily community located in the Hoover suburb of Birmingham. Cushman & Wakefield's Andrew Brown, Craig Hey and Jimmy Adams represented the seller in the $15.37 million transaction. Greystone's Steven Vainer originated an $11.6 million bridge loan featuring interest-only payments. The multifamily property was sold by SB Pacific Group. The buyer is a joint venture between 3MC Partners and Hinze Real Estate Partners.

09:37 EDT Alfi files quarterly, annual reports for 2021 - Alfi announced that it has filed with the Securities and Exchange Commission the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and amendments to each of the Company's previously filed Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021. The Company also filed with the SEC a Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. About Alfi, Inc.

09:36 EDT PureTech Health presents additional Phase 1 data for LYT-100 - PureTech Health announced the presentation of additional data for PureTech's LYT-100 at the American Thoracic Society 2022 International Conference. The data were shared in a scientific poster session and detailed the outcomes of a study in healthy older adults showing that LYT-100 demonstrated a lower incidence of adverse events compared to pirfenidone at comparable exposure levels. Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100 were reported in January 2022. The data support the upcoming registration-enabling studies in which PureTech plans to investigate LYT-100 in patients with idiopathic pulmonary fibrosis at the planned 550 mg three times daily dose as well as a dose with a higher total drug exposure than the currently approved dose of pirfenidone to evaluate if higher exposure could translate into improved efficacy. Pirfenidone is approved by the U.S. Food and Drug Administration for the treatment of IPF but is associated with significant tolerability issues that LYT-100, as a deuterated form of pirfenidone, is intended to reduce. PureTech intends to advance LYT-100 into late-stage clinical development for the treatment of IPF using a 505(b)(2) development path, beginning with a dose-ranging study evaluating six months of treatment with LYT-100 with topline results expected by the end of 2023. The double-blind, randomized, crossover Phase 1 study evaluated the tolerability of LYT-100 550 mg TID versus pirfenidone 801 mg TID in 49 healthy older adults aged 60-79, an age group consistent with that of the IPF patient population. As previously announced, the study was supportive of an improved tolerability profile for LYT-100 with 38% fewer subjects treated with LYT-100 experiencing any AEs compared with those treated with pirfenidon. The poster presented today details the incidence of AEs in the study population including the reduction in incidence of AEs in LYT-100 vs. pirfenidone administration in both fed and fasted subjects. The poster presented today details the incidence of AEs in the study population including the reduction in incidence of AEs in LYT-100 vs. pirfenidone administration in both fed and fasted subjects. Notably, LYT-100 at 550 mg TID dose met the criteria for bioequivalence for exposure compared to the FDA-approved dosage of pirfenidone - 801 mg TID - but with a lower Cmax.

09:31 EDT Avinger annouces KOL presentation, live case at vascular conferences - Avinger announced a key opinion leader presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany: the annual CLI Congress on May 6-7 and Masterclass Munster on May 9-10. The annual CLI Congress in Germany is regarded as one of the foremost forums in the world addressing the complex condition of critical limb ischemia. The Congress includes a comprehensive educational agenda on the treatment of patients with this severe form of PAD, with a focus on avoiding amputations. At the conference, Dr. Arne Schwindt, a vascular surgeon from St. Franziskus Hospital Munster in Germany, gave a podium presentation entitled "OCT-guided atherectomy." Dr. Schwindt is widely recognized as a leading global user and pioneer in the use of Avinger's OCT-guided therapies, including the Pantheris image-guided atherectomy devices. Dr. Schwindt's presentation featured patient cases treated with Pantheris to highlight the advantages of onboard OCT imaging in the preservation of limbs that would otherwise necessitate amputation due to CLI. Masterclass Munster is an annual regional conference with approximately 200 attendees and an agenda focusing on interventional PAD treatments. In a live case presented to the attendees, Dr. Schwindt demonstrated the advantages of Avinger's image-guided approach for the treatment of complex arterial disease. During the case, Dr. Schwindt used Avinger's Pantheris OCT-guided directional atherectomy device to successfully treat a 79 year-old woman suffering from permanent rest pain of the right foot caused by a total occlusion of the popliteal artery.

09:27 EDT Playtika invests $5M in card game developer ProDrops - Playtika is making a $5M seed investment in ProDrops, a developer of collection and trading card games for the gaming and eSports worlds. ProDrops was founded in 2021 by CEO, Omer Ziv, and Chief Technology Officer, Ido Perach. The investment, which is part of the company's first round of funding, will allow the team to accelerate development of its Rocket League card collecting add-on, which is supported by Israeli gaming plugins platform company, Overwolf, and will officially launch in 2023. The funding will also allow ProDrops to develop additional games and triple its workforce.

09:25 EDT Griffon to review range of strategic alternatives - Griffon announced that its board of directors has initiated a process to review a comprehensive range of strategic alternatives to maximize shareholder value including a sale, merger, divestiture, recapitalization or other strategic transaction. Griffon has retained Goldman Sachs & Co. as its financial advisor and Dechert LLP as its legal counsel to assist in the review process.

09:24 EDT Aprea Therapeutics acquires Atrin Pharmaceuticals in stock-for-stock transaction - On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash equivalents as of March 31, 2022 will be sufficient to meet its current projected operating requirements through the second half of 2023. With the acquisition of the Atrin programs, Aprea intends to shift its primary focus to the ATR inhibitor ATRN-119, which will be studied as both a monotherapy and in combination with standard of care in Phase 1/2a clinical trials in solid tumor malignancies. In parallel with ATRN-119 development, Atrin initiated separate programs for a second-generation ATR inhibitor, ATRN-354, with potentially improved potency and pharmacokinetics, as well as for a potentially highly potent and selective WEE1 inhibitor - ATRN-W1051. These programs are expected to enter IND-enabling studies in 2022 and Aprea anticipates filing Investigational New Drug applications for these programs in 2023. Furthermore, with the acquisition of Atrin, Aprea obtained an active proprietary development platform to drive the identification of new oncology drug targets and Christian Schade, our current Chairman and Chief Executive Officer will remain with Aprea along with Scott Coiante, our current Senior Vice President and Chief Financial Officer, and Greg Korbel will remain with Aprea, but will transition from his current role as Senior Vice President and Chief Business Officer to Senior Vice President and Chief Operating Officer. Our management team will be expanded with the appointment of Dr. Gilad, the former Chief Executive Officer of Atrin, who will be President of Aprea and Ze'ev Weiss, the former Chief Business Officer of Atrin, who will be the Chief Business Officer of Aprea. After the 2022 annual stockholder meeting of Aprea, Dr. Gilad will assume the role of Chief Executive Officer from Mr. Schade and Mr. Schade will continue as Executive Chairman of the Board of Directors. In conjunction with the transaction, the Aprea board was expanded to eight members. Immediately following the consummation of the transaction, the Aprea board will consist of, Dr. Gilad, Mike Grissinger, Rif Pamukcu, and Marc Duey, each of whom were members of the Atrin board who will join the Aprea board, and current Aprea Board members Christian Schade, Jack Henneman, Richard Peters and Bernd Seizinger. Christian Schade will remain the Executive Chairman of the Aprea Board for up to six months, and he would remain as Non-Executive Chairman thereafter. Aprea and Atrin have agreed to expand the Aprea board to nine members following Aprea's 2022 annual stockholder meeting. The Aprea Board plans to fill the remaining vacancy after such meeting. The acquisition of Atrin was structured as a stock-for-stock transaction whereby all of Atrin's outstanding equity interests were exchanged for a combination of shares of Aprea common stock and shares of Series A non-voting convertible preferred stock. Subject to Aprea stockholder approval, each share of Series A preferred stock will, at the option of the holder, convert into 10 shares of common stock, subject to certain beneficial ownership limitations set by each holder. On a pro forma basis and based upon the number of shares of Aprea common stock and preferred stock issued in the acquisition, holders of Aprea equity holders immediately prior to the acquisition will own approximately 41.2% of Aprea on an as-converted basis and former Atrin equity holders will own approximately 58.8% of Aprea on an as-converted basis immediately after these transactions. The acquisition was approved by the Board of Directors of Aprea and the Board of Directors and the requisite equity holders of Atrin. The closing of the transactions was not subject to the approval of Aprea stockholders. In connection with acquisition of Atrin, each holder of Aprea common stock as of immediately before the closing of the transaction will be entitled to a non-transferrable contingent value right. Holders of the CVR will be entitled to receive certain payments from proceeds received by Aprea, if any, related to the disposition, if any, of its legacy p53 reactivator assets during the 2-year period following the closing of the transaction. Immediately after the completion of the acquisition, Aprea is expected to have pro forma cash on hand, before transaction-related expenses, of approximately $48 million and cash runway through the second half of 2023.

09:21 EDT A2Z Smart Technologies launches smart carts with NTUC FairPrice - A2Z Smart Technologies announced a pilot program for its Cust2Mate Smart Carts with NTUC FairPrice Co-Operative. The first Cust2Mate Smart Carts will arrive at a new luxury FairPrice located in a shopping mall in the center of Singapore on July 15, 2022. The carts will be available on a limited basis beginning August 1, 2022 and will be available for all shoppers beginning September 1, 2022. Fully integrated with the FairPrice POS ecosystem, A2Z's state-of-the-art Cust2Mate Smart Cart streamlines the shopping experience by recognizing every purchased item and enabling in-cart payment so that shoppers skip lines, while also allowing retail grocers to direct shoppers to discounted products and in-store promotions to efficiently manage and move inventory.

09:20 EDT Loop Industries enters commercial supply agreement with Danone - Loop Industries announced a multi-year supply agreement with French food group Danone. The new 5-year agreement will supply Danone brands, including evian water, with Loop branded PET resin made from 100% recycled content. The resin will be supplied from the planned Infinite Loop Becancour plant which is currently anticipated to begin production in Q4 2024. In conjunction with this agreement, Danone and other Loop partners retained a globally recognized third-party independent engineering firm to execute a detailed due diligence report, which validated and reinforced the quality, effectiveness, and scalability of Loop Industries' technology. Loop and Danone have developed a long-standing relationship built on transparency and communication that supports Danone's circular packaging commitments on a global basis. Throughout this time, Loop Industries has continued to work diligently on perfecting its technology for commercial production on an international scale, including projects to build greenfield Infinite Loop facilities in Canada, France, and South Korea.

09:17 EDT Liquid Media expands content distribution partnership with Insight TV - Liquid Media announced a further expansion of the action-adventure sports content being distributed via its partnership with Insight TV, which reaches 400+ million households in 53 countries. "Our partnership with Insight has unlocked a significant global opportunity to expand the streaming footprint for select Liquid library content across an impressive worldwide distribution network," said Ron Thomson, CEO of Liquid Media. "With such compelling content chosen for distribution, we were excited but not at all surprised to see the analytics and SVOD revenue trending upward in the early months. By adding 50+ more captivating titles from our content library to Insight in the near term, we are aiming to further boost both reach and revenue for independent content creators and for Liquid."

09:17 EDT Capital Power announces 4.5-year contract renewal for Island Generation - Capital Power announced the execution of a 4.5-year Electricity Purchase Agreement, EPA, through October 2026 for its Island Generation facility with BC Hydro. The EPA is subject to regulatory approval by the British Columbia Utilities Commission, BCUC. "Island Generation has been providing reliable backup power to Vancouver Island and Metro Vancouver for two decades," said Brian Vaasjo, President and CEO of Capital Power. "It is the largest power generation facility on Vancouver Island, representing about one-third of total power capacity generation for the Island and has been a dependable system resource to BC Hydro by providing critical backup power and grid reliability. This 4.5-year EPA will provide BC Hydro customers with important contingency backup supply. We believe Island Generation will continue to be required for reliability purposes on Vancouver Island beyond the 4.5-year term. We continue to advocate for longer-term recontracting of Island Generation as part of our active participation in BCUC's public regulatory review process to finalize BC Hydro's Integrated Resource Plan," stated Mr. Vaasjo. Island Generation is a 275-megawatt natural gas-fired combined cycle facility located in Campbell River on Vancouver Island, BC. Capital Power acquired Island Generation in October 2010 when it was fully contracted under a 12-year tolling arrangement with BC Hydro that expired in April 2022.

09:13 EDT Celcuity announces $100M private placement - Celcuity announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors in a private placement for the purchase of common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred stock that is expected to result in aggregate proceeds to the Company of $100 million, before deducting placement agent fees and other offering expenses. The Company expects to use the net proceeds to advance clinical development of gedatolisib, including its planned Phase 3 clinical study, and for general corporate purposes. Venrock Healthcare Capital Partners is the lead investor in the private placement, and Commodore Capital, New Enterprise Associates, RA Capital Management, Soleus Capital and Brian Sullivan, the Company's Chief Executive Officer, are also participating. Investors will purchase shares of common stock and preferred stock at a price per share of $5.75. For each share of common stock and each 1/10 of a share of preferred stock purchased, investors will receive a warrant initially exercisable for preferred stock equivalent to 0.40 shares of common stock on an as converted basis. The exercise price of the warrants will be at a 40% premium to the price paid by investors for the initial shares of common stock purchased in the private placement. The preferred stock will be convertible into common stock at the holder's election, subject to certain limitations such as beneficial ownership and the approval by the Company's stockholders to increase the number of authorized shares of common stock sufficient to cover the shares of common stock issuable upon conversion of (i) the preferred stock purchased in the private placement and (ii) the shares of preferred stock that may be issued upon exercise of warrants purchased in the private placement. The warrants are initially exercisable for preferred stock and will convert into warrants to purchase common stock if the proposed increase in the Company's authorized common stock is approved by stockholders. The closing of the private placement is expected to occur shortly after the first patient enrolled in the Company's forthcoming Phase 3 clinical study receives their first dose of treatment at a clinical site located in the United States, provided that such date must occur on or before December 31, 2022. The Company expects to activate the VIKTORIA-1 study in mid-2022 and that the first patient receiving their first dose is expected to occur six to ten weeks later. The Company expects to report results for the first primary analysis of the VIKTORIA-1 clinical study in the second half of 2024. Additional details regarding the private placement will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission. Jefferies LLC acted as the sole placement agent for the private placement.

09:11 EDT Auddia releases initial data from launch of faidr mobile app - Auddia released initial consumer data in response to the launch of faidr, a mobile streaming app that lets consumers control the listening experience across any AM/FM radio station, to include listening without commercials. This initial data meets or exceeds the Company's internal goals for the faidr launch. Auddia launched faidr with 4,500 radio stations on February 15, 2022 and set a goal of 50,000 installs and 10,000 Monthly Active Users by the end of Q2. The Company believes that achieving these metrics, while driving the cost per install to $5 or less, is indicative of significant consumer interest in faidr, especially when considering that only music stations were active on faidr during the initial 90-day launch period. At the time of the faidr launch, the Company announced that it expected to release initial data after 90 days. faidr download rates, costs to drive downloads and initial MAU rates are all in-line with the Company's internal goals, and in some cases, ahead of target goals. At an average of $3.75, the current CPI after 60 days is under the $5 internal target the Company hoped to hit by end of Q2. Total downloads to date are 36,000 and on track to hit or exceed the goal of 50,000 by the end of Q2. With 24,800 MAUs as of today, the Company far exceeded its goal of having 10,000 MAUs by the end of Q2, and expects to continue to see strong growth in MAUs based on the current trends. At the end of Q2, Auddia will report updated metrics on the faidr launch in addition to a timeline for communicating subscription conversion rates.

09:10 EDT Fury Gold Mines announces completion of IP ground geophysical survey at Percival - Fury Gold Mines is pleased to announce the completion of a 29 line-kilometre Induced Polarization ground geophysical survey at the high-grade Percival prospect within the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. The mineralization at Percival has a clear resistivity signature and the survey has identified a number of similar resistivity anomalies that coincide with biogeochemistry gold and trace element anomalies over a 6.5-kilometre strike length. The survey covered eight of the fifteen previously announced biogeochemical targets along the Percival trend. This newly acquired data is being incorporated into the final drill targeting for the upcoming summer 2022 drill program at Percival. The survey identified discrete coincident resistivity and conductivity anomalies which correspond with the sulphide-rich silica breccia gold-bearing bodies at Percival. The Percival prospect, located 14km east of the Eau Claire deposit, is currently represented by a 400 metre by 100m mineralized footprint hosted within folded sulphidized and silicified breccias in an interbedded volcanic and sedimentary sequence represented by historical drill intercepts of 93.1m of 2.22 g/t gold, 9.0m of 6.26 g/t gold, 8.5m of 7.13 g/t gold and 2.0m of 8.47 g/t gold. The IP survey methodology is useful for fingerprinting the sulphide rich silica dominant Percival style of mineralization, by identifying the resistive silicified units coinciding with a highly conductive, response due to the high sulphides content. In the western portion of the survey iron formation in close proximity to highly conductive graphitic shales obscure the conductivity signature associated with the sulphide mineralization at Percival prospect, however, the mineralization is imaged as relative conductive lows adjacent to the graphitic shales. In the eastern portion of the grid, these graphitic shales are less prevalent, and the IP survey has defined a number of coincident resistivity and conductivity highs that the Company plans on evaluating and advancing to drill stage. The IP survey also confirmed the presence of NW / SE structures that appear to be an important control on mineralization observed at the Percival prospect. This structural trend coincides with a number of biogeochemistry anomalies and the technical team interprets these structures as a key component to concentrating gold mineralization along the Percival trend. This vector was previously derived from the interpretation of the biogeochemical and magnetics data. This structural trend is parallel to the regional fold axis that links the Percival and Serendipity prospects. The IP survey consisted of a total of 28.89 line-km across three distinct areas of the Percival trend covering eight of the fifteen previously announced biogeochemical targets. Lines ranged from 0.975 to 2.025 km with spacing of 125 to 250 metres. The survey was carried out using a pole-dipole electrode array with a nominal station spacing of 37.5m and readings ranging from n = 1 to n=20 allowing for a depth of survey of up to 325m.

09:08 EDT Voya Financial announces Stacy Hughes as CISO - Voya Financial (VOYA), announced that Stacy Hughes has joined the company as senior vice president and chief information security officer, or CISO. In this role, Hughes will be responsible for advancing Voya's vision and strategy for an information security program and supporting Voya's focus on providing products, solutions and technologies that help Americans become well planned, well invested and well protected. Hughes will drive alignment of Voya's information security investments and plans to deliver leading-edge security technologies and capabilities across Voya's enterprise infrastructure. She will lead the effort to anticipate and proactively mitigate information security risks, while also supporting business growth and innovation. Most recently, Stacy was the CISO at Global Payments (GPN).

09:06 EDT Neovasc regains compliance with Nasdaq minimum bid price rule - Neovasc announced that it has received written notification from the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq. As previously reported, on May 24, 2021, Neovasc received a letter from the Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until November 22, 2021, to regain compliance. In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(i), the Company requested and was granted a second 180-calendar day period, or until May 23, 2022, within which to evidence compliance with the $1.00 bid price requirement. On May 13, 2022, Neovasc received notification from the Nasdaq stating that since the closing bid price of the Company's common shares had been greater than US$1.00 per share for the last 10 consecutive business days, from April 29, 2022 to May 12, 2022, Neovasc was in compliance with Listing Rule 5550(a)(2) and this matter is now closed. The Company is also listed on the Toronto Stock Exchange and regaining compliance on the Nasdaq does not affect the Company's compliance status with such listing.

09:05 EDT Arthur J. Gallagher acquires Hruska Insurancenter - Arthur J. Gallagher acquired Mokena, Illinois-based Hruska Insurancenter. Terms of the transaction were not disclosed. Founded in 1956, Hruska Insurancenter is a retail property/casualty brokerage with a particular focus on serving commercial real estate clients, including condominiums and apartment complexes. The team also supports a range of other commercial and personal lines clients, primarily throughout Chicagoland and the upper Midwest. Charles J. Hruska, III and his associates will continue to operate from their Mokena location under the direction of Ryan Isaacs, head of Gallagher's Midwest region retail property/casualty brokerage operations.

09:03 EDT Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial - Inhibrx announced topline results from a Phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Data from this multi-country Phase 1 study are from 31 patients with AATD. Treatment was well tolerated with no severe or serious adverse events related to the study drug. Drug-related adverse events were predominantly mild and those few that were moderate in severity were all transient and reversible, with minimal or no symptomatic care. No safety-related or PK/PD-related signs of neutralizing anti-drug antibodies were observed. Dose-related increases in maximal and total INBRX-101 exposure occurred across the entirety of the single and multiple ascending dose ranges. To date, bronchoalveolar lavage fluid samples have been processed from two 80 mg/kg multiple ascending dose cohort individuals and confirm the presence of INBRX-101 in the lung fluid. Additionally, functional AAT levels were measured in plasma samples from 65 normal MM genotype individuals. This analysis revealed the 5th and 95th percentiles of functional AAT levels in the normal MM genotype individuals were 23 and 57 microM, respectively, with a median of 38 microM.

09:02 EDT MICT, Inc. says Tingo releases Q1 results - On May 10, 2022, MICT and Tingo announced they had executed a definitive agreement to merge and consolidate their operations to create a highly profitable Nasdaq-listed Fintech and Agri-Fintech company serving the African and Asian markets with a global expansion strategy. Earlier today, Tingo announced its results for the quarter ended March 31st, 2022 and filed its Quarterly Report on Form 10-Q. Tingo's press releases and filings can be found in the investor information section of its website: https://tingoinc.com/investor-information/press-releases/. With regard to the status of the merger, due diligence work is underway, and significant progress is being made on the transaction process.

08:56 EDT Griffon trading halted, news pending

08:54 EDT Volcon ePowersports signs MOU with BFGoodrich Tires - Volcon is collaborating with BFGoodrich Tires to potentially develop an optimized tire, tire pressure monitoring system and vehicle suspension system which will enhance electric UTV vehicle performance by the co-development of this combination. The two companies will work together on several phases of development which will be determined as they move forward. The Volcon Tech Innovation Group, VTIG, a division of Volcon that explores advanced technologies to enhance and evolve current and future Volcon products, will be the first UTV brand to work directly with BFGoodrich to co-develop this technology. The two teams will work together to leverage the power of the EV motor in tandem with BFGoodrich's ActivAir, the Central Tire Inflation System that makes real-time adjustments that aim to enhance the off-road performance and increase the battery range of Volcon's future UTV products. Additionally, Michelin North America will supply Volcon with the BFGoodrich Mud-Terrain T/A KM3 UTV Tire as standard on all 2023 Stag LE models. The collaboration is based on Volcon's mission to build products that connect people to outdoor experiences through the intentional blending of leading technology and design.

08:52 EDT Omniq announces award of $4M project from major T&L company - OMNIQ announced that it received an approx. $4M dollar project from a major transport and logistics, T&L, Company, first delivery for $1.2 M is expected to be supplied immediately and the balance of $2.8M during Q2 and Q3 of 2022. omniQ will supply Android-based rugged data collection, computing and communication equipment to the customer's various locations across the United States. The 3PL customer has annual revenue of over $10 billion and more than 10,000 employees. The multi-deploy agreement is valued at approximately $4 million. Shai Lustgarten CEO stated: "Once again we are privileged to enjoy the trust and loyalty of one of the largest T&L companies in the world positioning us as experts in providing Supply Chain solutions. This customer joins leading supermarket and retail chains, large Health care suppliers, Cities, Governments, security agencies and other demanding customers that rely on our solutions using state of the art technologies, proprietary AI based solutions, successfully serving multiple verticals".

08:50 EDT Nouveau Monde, Mason Graphite enter JV agreement on Lac Gueret project - Nouveau Monde Graphite and Mason Graphite are pleased to announce that they have entered into an investment agreement with a view towards the development and operation of Mason Graphite's Lac Gueret property. Highlights include: On closing, NMG and Mason Graphite to enter into an option and joint venture agreement pursuant to which the parties will collaborate to advance the Property, based in Quebec, Canada, with a view to form a joint venture; NMG to make a concurrent equity investment in Mason Graphite of an aggregate amount of up to C$5.0 million payable in two instalments; Conditions for the formation of the Joint Venture include: a minimum of C$10.0 million of expenditures from NMG on the Property, and the completion of an updated feasibility study on the Property based on an estimated production scale of a minimum of 250,000 tonnes per annum of graphite concentrate, to be ascertained based on customer demand as well as technical and environmental possibilities. The latest feasibility study published by Mason Graphite is based on 51,900 tonnes per annum; Assuming the exercise of the option and formation of the Joint Venture, NMG's and Mason Graphite's interest in the Joint Venture to be 51% and 49%, respectively, and NMG to be appointed as operator of the Joint Venture; Joint Venture to be funded by NMG and Mason Graphite on a pro rata basis; failure to fund work program commitments in the Joint Venture to result in a 1% dilution for each unfunded tranche of C$5.0 million; The Joint Venture will have full access to NMG's Phase-1 natural graphite flake concentrator plant currently in operation in Saint-Michel-des-Saints, Quebec in order to accelerate the qualification and commercialization of its graphite, which has been proven instrumental as per NMG's recent successful experience. To date, NMG has invested approximately C$30.0 million in the Demonstration Plant; The Joint Venture will benefit from NMG's depth of personnel and commercialization capabilities; NMG currently employs nearly 100 full-time employees, most of whom are focused exclusively on graphite advanced materials, making it one of the largest natural graphite-focused organizations in North America and the ideal partner for the project; The Property is notably sizable, with a total Measured and Indicated Resource of 65.5 million tonnes grading 17.2% Cg, and carries one of the highest grades of graphite ore globally with a Proven and Probable Reserve totalling 4.7 Mt grading 27.8% Cg. Mason Graphite received the governmental authorization for the Property, via the issuance of the Decree 608-2018 by the Quebec Government; NMG and Black Swan Graphene, a subsidiary of Mason Graphite, intend to enter into a non-binding letter of intent for the implementation of Black Swan's graphene processing technology in NMG's Demonstration Plant, which has a design throughput of 3.5 tonnes of ore per hour, the equivalent nameplate production capacity of approximately 1,000 tonnes of graphite concentrate per annum, using NMG's ore grading an average of 4.5% graphitic carbon, in order to establish a fully integrated facility from graphite ore to graphene finished products; and The entering into of the Option and JV Agreement is subject to the approval of the TSX Venture Exchange and the shareholders of Mason Graphite at a special meeting of shareholders of Mason Graphite to be called and expected to be held on or about the first week of July 2022.

08:50 EDT Foothills Exploration provides UAS joint venture update - Foothills Exploration announces an update on its joint venture with Perspectum Drone Inspection Services. Natural hydrogen exploration is gaining momentum globally as demand for low-cost carbon-free hydrogen continues to grow exponentially. The Company plans to start marketing the joint venture's drone reconnaissance services for the delineation of the lands contained in these 18 exploration concessions. The Company, through its joint venture, also plans to begin unmanned aerial surveys over the lands in the White Lightning Prospect through its participation agreement with Pristine Energy, Inc. Update on Joint Venture with Perspectum: HHe Exploration Technologies has integrated its hydrogen sensor with its Unmanned Aerial Vehicle and it has been test flown to evaluate the navigational and stability performance of the platform. Field testing under optimum conditions is being pursued but to date HHe has experienced unusually cold and snowy spring weather conditions at its test site. HHe expects to be in the field testing the sensor detection and mapping software in the coming days.

08:47 EDT Neoleukin treats first patient in Phase 1 trial of NL-201 w/ KEYTRUDA - Neoleukin Therapeutics announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin's NL-201 in combination with Merck's anti-PD-1 therapy KEYTRUDA, as part of Neoleukin's ongoing Phase 1 trial in patients with relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study, which is being conducted through a clinical collaboration and supply agreement with Merck. The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity.

08:45 EDT Surrozen publishes article on SZN-1327 data in IBD - Surrozen announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology. The results seen with one of Surrozen's proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease. Multiple molecules were evaluated in an acute Dextran Sodium Sulfate mouse colitis model, including SZN-1326, a Wnt mimetic with specificity to Frizzled 5 and low-density lipoprotein receptor-related protein 6. SZN-1326 demonstrated the most rapid and robust repair of the injured colon epithelium without affecting normal epithelium and without causing hyperplasia. Current management of moderate to severe ulcerative colitis leaves a significant unmet medical need for drugs that can directly repair and regenerate the intestinal epithelium and can quickly induce clinical and histological remission in patients. Histologic remission is now increasingly regarded as an important treatment objective for UC, as the absence of microscopic disease activity predicts a better clinical course. There are currently no approved therapies that directly repair the epithelial barrier. Additionally, treatment options are limited once anti-inflammatory agents have failed. In the intestine, Wnt signaling plays an important role in maintaining integrity of the epithelium as part of tissue homeostasis and during injury repair. Since Wnt signaling in the intestinal mucosa is critical for repairing the intestinal epithelium, modulation of Wnt signaling has the potential to achieve epithelial regeneration, reduction in inflammation, improvement in disease control and histological remission and mucosal healing. Surrozen designed an antibody-based platform that generates potent Wnt mimetics, which specifically target select Fzd receptors and co-receptors. In this paper, the effects of multiple Wnt mimetics were evaluated to identify the desired regenerative effects on injured tissue and absence of hyperplasia in uninjured tissues.

08:43 EDT Cellectis presents research data on novel CAR T-cell at ASGCT - Cellectis will present its first research data on the development of a novel universal CAR T-cell with immune-evasive properties using TALEN-gene editing, at the American Society of Cell and Gene Therapy, ASGCT, Annual Meeting being held on May 16-19, 2022. This novel immune-evasive CAR T-cell scaffold evades NK cell and alloresponsive T-cell attacks and imparts efficient antitumor activity in vitro and in vivo. Cellectis' novel immune-evasive CAR T-cell , was developed using a combination of TALEN-mediated gene editing and adeno-associated virus dependent gene insertion. Research data showed that: TRACCARB2MHLAE overcame alloresponsive T-cell and NK cells attacks. The immune-evasive property of TRACCARB2MHLAE was similar toward NK cells from healthy donors, acute myeloid leukemia patients and acute lymphocytic leukemia patients. TRACCARB2MHLAE T-cells exhibit prolonged antitumor activity in the presence of cytotoxic levels of NK cells.

08:41 EDT Biofrontera Inc. announces pricing of $9.4M private placement - Biofrontera announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock and a warrant to purchase one share of common stock is $2.75. The warrants have an exercise price of $2.77 per share, will be exercisable six months after issue date, and will expire five and one-half years from the issuance date. Roth Capital Partners and The Benchmark Company are acting as the exclusive placement agents for the private offering. The gross proceeds from the private placement offering are expected to be approximately $9.4 million. The private offering is expected to close on or about May 17, 2022, subject to the satisfaction of customary closing conditions.

08:40 EDT Occidental Petroleum announces cash tender offers for certain senior notes - Occidental announced that it has commenced cash tender offers to purchase its outstanding notes in three separate pools. Occidental's obligation to accept for purchase, based on the Acceptance Priority Levels set forth in the columns entitled "Acceptance Priority Level" in the tables below, and pay for Notes that are validly tendered and not validly withdrawn is limited to an aggregate amount of $700,000,000 for all of the Pool 1 Notes, $650,000,000 for all of the Pool 2 Notes and $650,000,000 for all of the Pool 3 Notes. The Offers are being made on the terms and subject to the conditions set forth in the Offer to Purchase dated May 16, 2022 . apitalized terms used in this release but not otherwise defined have the meaning given in the Offer to Purchase. The Offers will expire at 5:00 p.m., New York City time, on May 20, 2022, unless extended or earlier terminated as described in the Offer to Purchase. Holders of the Notes may withdraw their validly tendered Notes at any time at or prior to 5:00 p.m., New York City time, on May 20, 2022, unless extended. Holders are urged to read the Offer to Purchase carefully before making any decision with respect to the Offers.

08:38 EDT SharpLink Gaming announces partnership with WPT Global - SharpLink Gaming announced that its wholly-owned subsidiary Trenfront Marketing/Poker Affiliate Solutions, acquired in the FourCubed transaction in December 2021, has been selected by WPT Global to manage the new WPT Global affiliate program as its Master Affiliate. WPT Global is an exciting new online gaming operator that has licensed the World Poker Tour brand to market and promote its gaming platform.

08:36 EDT Turning Point Therapeutics appoints Steve Sabus as CCO - Turning Point Therapeutics announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members.

08:35 EDT Transcode Therapeutics announces planned milestones - TransCode's goals to continue to advance its portfolio include: TTX-MC138 - Submission to FDA of an eIND application for its First-in-Human clinical trial. Completion of a FIH Phase 0 clinical study intended to demonstrate quantifiable evidence of delivery of radiolabeled TTX-MC138 to metastatic lesions in advanced solid tumors; measure pharmacokinetics and biodistribution in vital organs and other tissues; potentially inform therapeutic dose levels based on microdose results; and validate delivery for the TTX pipeline more broadly, potentially opening-up additional relevant RNA targets that have been previously undruggable due to challenges with RNA delivery. Concurrent completion of IND-enabling studies to support filing an IND application for a Phase I clinical trial of TTX-MC138. Publication of preclinical results supporting the lead therapeutic candidate, TTX-MC138, in pancreatic cancer and glioblastoma multiforme. Publication of preclinical results supporting therapeutic candidate, TTX-RIGA. Continuation of preclinical studies for therapeutic candidates TTX-RIGA, TTX-siPDL1, and TTX-siLIN28B. Continuation of discussions regarding potential partnerships. File for Orphan Drug Designation for its lead therapeutic candidate in additional tumor indications.

08:34 EDT Vyant Bio expects cash to fund operations well into 2023 - Cash and cash equivalents totaled $16.4 million as of March 31, 2022. The Company implemented two new vehicles to facilitate the raising of additional equity capital at the Company's option with the finalization of the Lincoln Park Equity line of credit allowing access to raise up to $15 million, as well as signing a $14.5 million ATM with Canaccord Genuity. The Company's current cash balances, future proceeds from the sale of vivoPharm and future proceeds from the equity line of credit and ATM are expected to fund operations well into 2023.

08:32 EDT Steel Dynamics to acquire Mexican metals recycling company Roca Acero - Steel Dynamics has entered into a definitive agreement to acquire the equity interest of Roca Acero to be funded with available cash. Roca is headquartered in Monterrey, Mexico and operates a ferrous and nonferrous scrap metals recycling business. Roca's primary operations are comprised of four scrap processing facilities, positioned near high-volume industrial scrap sources located throughout Central and Northern Mexico. These combined facilities currently ship approximately 575,000 gross tons of scrap annually and have an estimated annual processing capability of approximately 850,000 gross tons. This transaction is subject to customary closing conditions and receipt of required regulatory approvals.

08:30 EDT ManTech trading resumes

08:29 EDT WISeKey presents 'The Code to Metaverse' at Davos - WISeKey International announces that it will hold its 14th Annual Cybersecurity Roundtable in Davos on Wednesday, May 25, at the Piano Bar of Hotel Europe. Inspired at Davos through interactive workshops, The transHuman Code www.transhumancode.com is a bestselling book co-authored by Carlos Moreira and David Fergusson, released in June 2019 and subject of the forthcoming TV series. Since 2007, Geneva headquartered cybersecurity pioneer WISekey, a WEF global growth company since 2007, has hosted the cybersecurity roundtable at the Europa Hotel. As WISekey has evolved their business focus, the event has expanded to become a full evening of thought leadership and entertainment to include business, spiritual, philanthropic and policy making leaders. This year The Code to The Metaverse, will be introduced at Davos on Wednesday May in a broader partnership with NBC, who will be producing a 12 part multi-media series to include broadcast, event and social media programming. Grounded in a human-centric foundation, The transHuman Code provides an ethical platform for developers, enablers and users of new technologies to prioritize keeping people at the center of gravity in the relationship between woman/man and machine. With its roots in the development of secure identity management, WISeKey has stood at the forefront of providing greater security for data authentication since 1999. In the future, The transHuman Code platform, secured by WISeKey, could seamlessly ensure that technological innovations protect humans in the all environments. Our co-existence with artificial intelligence will challenge all conventions of ethical norms as we have known them, as we continue to digitize our work environment, our social interaction, and our physical activities. Recent developments have forced governments around the world to take steps to quickly understand how Metaverse, this new frontier of innovation, is challenging the traditional conception of Sovereignty. With data being stored virtually on the Metaverse anywhere in the world and government employees and citizens using information technology systems that are hosted and operated from anywhere, the expected sovereign rights over that date on the Metaverse needs to be reconsidered. Many information technology companies are telling governments that that their versions of the Metaverse will be enough to ensure sovereignty over their data and citizens. Others are stating that new legislation is needed to protect citizens. All in all, the solutions they propose are partial and unsatisfactory.

08:28 EDT Aeterna Zentaris urges shareholders to vote for proposed share consolidation - Aeterna Zentaris announced that its Virtual Annual General and Special Meeting of shareholders will be held on June 21, 2022, at 10:00 a.m. Management and the board of directors urge the Company's shareholders of record to vote "FOR" the resolution authorizing the Board to approve a share consolidation of the Company's issued and outstanding common shares. The platform for the virtual AGM will provide shareholders the ability to listen to the AGM live, submit questions and submit their vote during the AGM. Online check-in will begin 15 minutes prior to the start of the AGM, at 9:45 a.m. The AGM will begin promptly at 10:00 a.m. on June 21, 2022. A management information circular describing the proposed share consolidation and other items of business to be considered at the AGM will be mailed to shareholders in the coming days. Remaining on the Nasdaq Capital Market is a critical piece of the Company's performance, corporate visibility and overall awareness of Aeterna Zentaris to the investor base. If the Company fails to meet a minimum bid price for its common shares above US$1.00, for a minimum of at least 10 consecutive days before July 26, 2022, the Company could be delisted from The Nasdaq Stock Market, which could have serious consequences for the Company. Accordingly, the Company expects to file a management information circular in the coming days which will include a resolution for shareholders to provide the Board with the authority to consolidate the common shares at a ratio within the range of between five and 25 pre-consolidation common shares for every one post-consolidation common share. The Company expects that the Share Consolidation will allow for the common shares to continue to be listed on the Nasdaq, and ensure compliance with the Nasdaq's continued listing standard that common shares maintain a minimum bid price of US$1.00 per share. As previously announced, on July 28, 2021, the Company received a letter from the Listing Qualifications Department of the Nasdaq, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common shares for the prior 30 consecutive business day period, the Company no longer satisfied Nasdaq Listing Rule 5550(a)(2). In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted a grace period of 180 calendar days, through January 24, 2022. On January 26, 2022, the Company announced that the Nasdaq granted the Company an additional 180 calendar day period, through July 26, 2022, to comply with the Standard. In advance of the Deadline, the Board believes it is in the best interests of the Company to obtain shareholder approval at the Meeting to implement the Share Consolidation.

08:26 EDT Lantheus presents results from analysis of PYLARIFY PSMA scan - Lantheus presented results from a retrospective analysis of quantitative PYLARIFY PSMA scan indices as a response imaging-biomarker to androgen deprivation therapy in veterans with newly diagnosed metastatic prostate cancer. Using PYLARIFY AI to locate PSMA-avid lesions and track changes over time, investigators were able to determine that the change in the automated PSMA scan indices for total lesion volume, and also separately in bone and lymph node were all significantly consistent with PSA response following therapy. The findings support further exploration of PYLARIFY AI as a tool to quantify treatment response not only in at the overall disease burden but also at the lesion level. The study included a retrospective analysis of 30 treatment naive prostate cancer patients who had undergone androgen deprivation therapy with and without radiation. PSMA scans were performed prior to treatment and at least six months after initiation of treatment. The images of all patients were analyzed by PYLARIFY AI which was used to locate PSMA-avid lesions and track changes over time. The continuous change in quantitative PSMA indices was compared with the change in PSA. At treatment follow-up, patients had an average PSA decline of 97%.

08:24 EDT Zentek appoints Wendy Ford as CFO, Brian Bosse to focus on COO role - Zentek announced that Wendy Ford has been appointed as the new CFO for the organization. Ford has more than three decades of experience in finance and accounting leadership roles for both private and publicly traded companies. Brian Bosse will transition from his role as CFO to focus his efforts on overseeing operations as COO of Zentek, effective immediately. Most recently, Ford served as VP of Finance and CFO of Mancor Industries, a precision manufacturer of metal components and sub-assemblies.

08:23 EDT iCAD announces research on ProFound AI Risk for Digital Breast Tomosynthesis - iCAD announced that clinical research supporting ProFound AI Risk for Digital Breast Tomosynthesis - the world's first clinical decision support tool that provides an accurate short-term breast cancer risk estimation based on age, breast density and mammographic features - was recently published in the peer-reviewed journal, Science Translational Medicine. In the study, which involved 154,200 women screened at four participating U.S. screening sitesii using DBT from 2014-2019, researchers at the Karolinska Institutet in Stockholm, Sweden found ProFound AI Risk accurately determined women who were at a higher risk of developing breast cancer, with an area under the receiver operating characteristics curve of 0.82i. "iCAD's Breast AI Suite offers a complete portfolio of unrivaled breast cancer detection, density assessment, and short-term risk evaluation AI solutions, and we are pleased to see this compelling data further validate the clinical value of ProFound AI Risk, the latest addition to our breast AI portfolio," said Stacey Stevens, President and CEO of iCAD, Inc. "Physicians have traditionally estimated breast cancer risk by examining the patient's known risk factors, such as family history, but about 85% of breast cancers occur in women who have no family history of breast cancer.iv Additionally, traditional long-term risk models may not be as accurate at estimating a woman's risk of developing breast cancer, as their average AUC is around 0.60.v ProFound AI Risk offers a more individualized approach, as it includes a woman's mammography images and focuses on one-to-two-years in the future, which provides critical information that can help clinicians personalize breast cancer screening regimens for patients based on their individual risk of developing cancer before or at their next screening."

08:19 EDT Palo Alto Networks and Deloitte expand cybersecurity partnership - Palo Alto Networks and Deloitte announced the expansion of their existing strategic alliance to offer managed security services to their shared U.S. clients, making Palo Alto Networks cybersecurity technology portfolio available in managed offerings from Deloitte. Expanded solutions offered as managed services will include: Zero Trust Enterprise Enablement; Multicloud Automation and Orchestration; Managed Cyber Defense and Cyber 5G.

08:14 EDT Impel NeuroPharma expects cash to fund operations into 2024 - As of March 31, 2022, Impel had approximately $130 million in cash and cash equivalents. The Company projects, based on its current operating plan, it has sufficient capital to fund operations into 2024.

08:10 EDT Aerovate Therapeutics expects cash to fund operations into 2H25 - We expect that our cash, cash equivalents and short-term investments will be sufficient to fund our operations into the second half of 2025, based on our current operating plan.

08:06 EDT Galectin Therapeutics expects cash to fund operations through May 2023 - As of March 31, 2022, the Company had $31.6 million of cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least May 16, 2023.

08:05 EDT Greenland Technologies selects Baltimore County for manufacturing expansion - Greenland Technologies has officially selected Baltimore County, Maryland for the next phase of the company's major U.S. expansion. With the formal selection of Baltimore County, Greenland plans to now move forward with an approximately 54,000 square-foot manufacturing facility, where it plans to create new full-time jobs. The facility which is expected to formally open in July, is central to the company's strategy of supporting the increased customer demand for its expanding line of electrical industrial vehicles. To support its expansion, the company has submitted a notice of intent to utilize the state's More Jobs for Marylanders program, administered by the Maryland Department of Commerce. The More Jobs for Marylanders program incentivizes new and existing manufacturers to create new jobs in the state, and to non-manufacturers that locate or expand in Maryland Opportunity Zones.

08:04 EDT Carlyle to acquire ManTech for $96 per share in $4.2B enterprise value deal - ManTech (MANT) announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firm Carlyle (CG) in an all-cash transaction with a total enterprise value of approximately $4.2B. Under the terms of the transaction, ManTech shareholders will receive $96.00 per share in cash. The transaction was unanimously approved by ManTech's Board of Directors, which recommends that ManTech shareholders vote in favor of the transaction. The transaction is expected to close in the second half of calendar 2022, subject to approval by ManTech shareholders, receipt of regulatory approvals and other customary closing conditions.

08:03 EDT Energy Vault names Josh McMorrow as chief legal officer - Energy Vault Holdings announced the appointment of Josh McMorrow as the company's Chief Legal Officer. "I am pleased to welcome Josh as the newest member of our leadership team," said Robert Piconi, Chairman, Co-Founder and CEO, Energy Vault. "Josh's broad international experience spanning several relevant industries, combined with his deep expertise in transactional and regulatory matters, will be a tremendous asset to the company." McMorrow is responsible for overseeing Energy Vault's legal, regulatory, IP and compliance functions, as well as all legal aspects of its strategic and commercial partnerships as the company continues to scale its operations and expand its global footprint.

08:00 EDT Rekor Systems trading resumes

07:58 EDT Clear Secure authorizes $100M share repurchase - Clear Secure has authorized a share repurchase program pursuant to which the company may purchase up to $100M of its Class A Common Stock. The repurchase program has no expiration date and may be modified, suspended, or terminated at any time. Repurchases under this program will be funded from Clear's existing cash and cash equivalents or future cash flow. As of March 31, Clear had $663M in cash and cash equivalents, restricted cash, and marketable securities.

07:58 EDT Clear Secure authorizes $100M share repurchase - Clear Secure has authorized a share repurchase program pursuant to which the company may purchase up to $100M of its Class A Common Stock. The repurchase program has no expiration date and may be modified, suspended, or terminated at any time. Repurchases under this program will be funded from Clear's existing cash and cash equivalents or future cash flow. As of March 31, Clear had $663M in cash and cash equivalents, restricted cash, and marketable securities.

07:56 EDT Monarch Mining appoints Adams to board of directors - Monarch Mining (GBARF) announce the appointment of Renaud Adams as a director of the Corporation effective June 30, 2022. MAdams will replace Christian Pichette, who is retiring from his position of director. Renaud Adams has over 25 years of experience in the mining industry and has been President and Chief Executive Officer of New Gold (NGD) since 2018.

07:55 EDT FTI Consulting appoints Winter as Senior Managing Director - FTI Consulting announced the appointment of Anne Winter as a Senior Managing Director within the Company's Health Solutions practice, where she will focus on Medicaid managed care and the pharmaceutical industry. Winter joins FTI Consulting from Health Management Associates, where she consulted with clients on Medicaid market strategy.

07:54 EDT Sabina Gold & Silver provides progress update for Goose Mine Development - Sabina Gold & Silver provides an update on advancements of the Goose Mine development at the Company's 100% owned Back River Gold District in Nunavut, Canada. The Goose Mine is the Company's first mine on the 80 km long Back River Gold District, a multi-generational mining district already with a high-grade world class gold endowment. The first quarter of 2022 culminated in one of the most important milestones for the Company to date. Debt, streaming and equity financings were completed with a total of over C$800M arranged, well in excess of the requirements of the 2021 Updated Feasibility Study. More importantly, with financing in hand, pre-construction, logistical and procurement activities have accelerated. In anticipation of the financing, Sabina had prepared tender documents and purchase orders which enabled the Company to quickly procure critical components necessary for this year's sealift. The UFS CAPEX estimate was C$610M. Of that, approximately C$218M was identified as direct equipment and materials purchases. Earthworks at the plant site are ~67% complete, which reflects an overall Project civil works completion rate of ~40%. To date, the Project is trending an ~10% quantity reduction from UFS estimates.

07:52 EDT WPD Pharmaceuticals signs annex to license agreement with WFUHS - WPD Pharmaceuticals announces that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences, WFUHS. On April 22, 2022 WPD Pharmaceuticals Sp. z o.o., the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2, WPD signed Annex No. 1 to the License Agreement on June 30, 2019. The original License Agreement with WFUHS has been in place since November 28, 2017, and both WPD and WFUHS have worked collaboratively since then. WPD and WFUHS have confirmed that the Licensed Know-How scope of Annex No.2 is larger than the previous agreement, and concerns information received from WFUHS related to, directly or indirectly, the subject matter of the patent rights or necessary or useful for the development, use or manufacture of the Licensed Products of which a copy is submitted to WPD by WFUHS under the License Agreement. WPD and WFUHS also confirm that the patent rights also cover US 11,136,367 patent as well as any patent applications or patents claiming priority to this patent, any of its foreign equivalents, any patent issued from that patent, as well as any re-examinations, reissues, substitutes, renewals, extensions thereto, or supplementary protection certificates based thereon.

07:51 EDT Viemed Healthcare provides update on appeal of claims related to OIG report - Viemed Healthcare is providing an update concerning the Company's appeal of claims related to findings from the U.S. Department of Health and Human Services Office of Inspector General, OIG, in a May 2021 report. Based on an objective and independent review of patients' medical records, the Centers for Medicare and Medicaid Services', CMS, Qualified Independent Contractor, QIC, responsible for evaluating the Company's Reconsideration appeals determined that approximately 77% of the claims it reviewed were medically necessary and properly payable under Medicare rules and regulations, overturning OIG's and CMS's initial recommendations and determinations. "The success of our latest round of appeals is an extremely positive development for patients and their families who depend on payors to hold up their end of the health care delivery network," said Casey Hoyt, Viemed's CEO. "We wholeheartedly believe in protecting and advancing the rights of these patients to have access to the care prescribed by qualified licensed physicians. As a leader in the respiratory care industry, we will continue to support responsible rulemaking and other initiatives to ensure that the best care remains available to those in need."

07:48 EDT Jushi expands product offerings, launches solventless cannabis extracts - Jushi Holdings launched the Company's first line of solventless live rosin extracts by its award-winning brand The Lab, famous for delivering high-quality, precision vape products and concentrates. The new top-shelf product line includes a 0.5g vape extract cartridge available now and 1g jarred concentrates coming soon for purchase exclusively at BEYOND / HELLO store locations in Pennsylvania under the name, The Lab Solventless Live RSN. In addition, throughout the summer, it is expected to launch at the Company's locations in Massachusetts, Nevada, and Virginia, pending regulatory approvals. "Consumer demand for live rosin cartridges and concentrates is on the rise," said Jushi Chief Executive Officer, Chairman, and Founder Jim Cacioppo. "Forged solely by the forces of nature, The Lab Solventless Live Rosin line captures the essence of whole premium flower, sets a new standard for quality in this fast-growing cannabis category, and brings customers some of the purest cannabis products available on the market today." Cacioppo went on to say, "Solventless products represent the pinnacle of extraction, as they capture the fullest expression of cannabinoids, terpenes, and flavonoids unique to each cultivar in concentrated form. Initially a niche category confined to dabbable concentrates, the demand for solventless is on the rise and there is a growing presence of solventless vapes and edibles with solventless inputs in markets throughout the country. Using some of the most innovative proprietary extraction technologies, we look forward to continuing to introduce new cannabis products that raise the bar across all product categories."

07:46 EDT Kinetik Holdings publishes sustainability-linked financing framework - Kinetik published its Sustainability-Linked Financing Framework, which links its Environmental, Social and Governance, ESG, commitments to the Company's broader financing strategy. "Together with our upcoming Sustainability Report to be released this summer, today's announcement strengthens our commitment to positively impact climate change and build an even more diverse and inclusive culture in our workplace," said Jamie Welch, President and CEO. "We strongly believe that integrating sustainability initiatives into our business decisions and financing strategy is essential to creating value for our stakeholders and is quite simply good business. These measures accelerate our move towards achieving net-zero greenhouse gas emissions by 2050 while also advancing our overall commitment to diversity, equity and inclusion." The following key performance indicators have been selected to measure progress against Kinetik's environmental and social sustainability performance targets: Greenhouse Gas Emissions Intensity; Methane Emissions Intensity; Female Representation in Corporate Officer Positions. These KPIs provide transparency and ensure meaningful progress is made towards Kinetik's SPTs, which align with Kinetik's long-term ESG initiatives and commitments. The designated SPTs are as follows: Reduce GHG emissions intensity by 35% by 2030, relative to the 2021 baseline. Reduce methane emissions intensity by 30% by 2030, relative to the 2021 baseline. Increase female representation in corporate officer positions to 20% by year end 2026.

07:45 EDT Aerojet Rocketdyne board formally reprimands Lichtenstein over CEO approaches - The company said, "After extensive deliberation, the Committee determined as follows: 1. Extensive questioning and demands for information were communicated by Mr. Lichtenstein to Ms. Drake and other members of executive management in numerous communications in the months prior to and following the signing of the Lockheed Martin merger agreement. Those questions and demands for information generally related to business and financial matters and "contingency planning" if the Lockheed transaction were not to proceed. Mr. Lichtenstein's conduct did not constitute harassment or retaliation and was not improper under applicable Company policies or law. 2. Mr. Lichtenstein had communications with third parties outside the Company concerning the merger with Lockheed and the Company's CEO. Specifically, notwithstanding Mr. Lichtenstein's stated support for the merger, he made comments expressing skepticism concerning the likelihood of the merger being approved, and approached two parties to inquire regarding their interest in becoming CEO if the merger did not close and criticizing Ms. Drake's performance. At least one of these inquiries, and likely both, were made after Mr. Lichtenstein received the Guidance Memo. The Board had not authorized a CEO search. Mr. Lichtenstein acted improperly in taking those actions, including by failing to follow the directives given to him in the Guidance Memo. This memorandum is a formal reprimand for that conduct, and a mandate to Mr. Lichtenstein that he comply with the Company's Code of Conduct and make no statements or communications to persons external to the Company concerning the Company's CEO, any search for a new CEO, management tenure or succession generally, or the strategic direction of the Company, unless specifically pre-approved by the Board, the statements or communications are made to stockholders as part of his efforts concerning the election of directors at the next annual meeting, or the statements or communications are made as part of his efforts seeking suitable persons to serve as CEO of the Company in the event his nominees are elected." are elected.

07:43 EDT Dyne Therapeutics presents new in vivo data from DYNE-101 - Dyne Therapeutics is presenting new in vivo data from DYNE-101, its myotonic dystrophy type 1, DM1, candidate, at the American Society of Gene & Cell Therapy, ASGCT, 25th Annual Meeting today demonstrating robust knockdown of DMPK RNA in multiple muscles with low monthly dosing. "We are excited to present these new data that show monthly dosing of DYNE-101 led to a substantial knockdown of toxic human nuclear DMPK RNA in cardiac and skeletal muscle in the hTfR1/DMSXL mouse model as well as reduction of wild-type DMPK RNA in muscles of non-human primates. Additionally, GLP toxicology data support a favorable safety profile for our DM1 candidate," said Oxana Beskrovnaya, Ph.D., Dyne's chief scientific officer. "These findings combined with previous data demonstrating correction of splicing, support the potential for DYNE-101 to be a disease-modifying therapy with low, infrequent dosing. We look forward to evaluating DYNE-101 in our planned global multiple ascending dose clinical trial in patients with DM1." The hTfR1/DMSXL model expresses the human transferrin 1 receptor and carries a human DMPK gene with more than 1,000 CTG repeats that represents a severe DM1 phenotype. In the hTfR1/DMSXL model, DYNE-101 achieved enhanced toxic human nuclear DMPK RNA knockdown in skeletal and cardiac muscle with four monthly doses of 5 mg/kg relative to a single dose. Importantly, the level of DMPK RNA knockdown observed with this 5 mg/kg repeat dosing regimen was comparable to that observed previously with a single dose of 10 mg/kg of DYNE-101.

07:41 EDT Natera co-founder and Executive Chairman Matthew Rabinowitz acquires 470K shares - Natera's co-founder and Executive Chairman Matthew Rabinowitz, together with his family's trust, have recently acquired a total of 470,000 shares of Natera stock through the purchase of additional shares on the open market and from the exercise of stock options. Rabinowitz and his family trust have spent over $10M to increase ownership in the company. Natera's executive leaders and non-employee directors have elected to take 100% equity compensation for the remainder of 2022. In addition, in March 2022, Roelof Botha, lead independent director of Natera's board of directors and partner at Sequoia Capital, invested $5M to purchase shares of Natera's stock on the open market.

07:41 EDT Loop Industries enters multi-year supply agreement with Danone - Loop Industries announced a multi-year supply agreement with French food group Danone SA. The new five-year agreement will supply Danone brands, including evian water, with Loop branded PET resin made from 100% recycled content. The resin will be supplied from the planned Infinite Loop Becancour plant which is currently anticipated to begin production in Q4 2024.

07:39 EDT Galera Therapeutics expects cash to fund operations into H2 of 2023 - As of March 31, 2022, Galera had cash, cash equivalents and short-term investments of $60.9 million. Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements into the second half of 2023.

07:37 EDT Century Therapeutics expects cash to fund operations into 2025 - Cash, cash equivalents, and investments were $466.4 million as of March 31, 2022, as compared to $358.8 million as of December 31, 2021. The Company expects its cash, cash equivalents, and marketable securities will support operations into 2025.

07:36 EDT Digital World Acquisition sees Trump Media transaction to close in second half

07:35 EDT Vera Therapeutics announces upcoming milestones - Upcoming Milestones: Two presentations featuring new clinical data from the Phase 2a JANUS clinical trial of atacicept in patients with IgA nephropathy and renal data from a post-hoc analysis of the Phase 2 APRIL-SLE study evaluating atacicept in patients with systemic lupus erythematosus are scheduled at the 59th European Renal Association European Dialysis and Transplant Association Congress being held May 19-22, 2022. The 12-week results from the interim analysis of a Phase 2 study in BKV viremia among kidney transplant recipients are scheduled to be presented at the American Transplant Conference on June 4, 2022. MAU868 has been to be well tolerated and showed a greater proportion of subjects with decrease in BKV plasma viral load versus placebo. Plan to initiate in the second half of 2022 a randomized, double-blinded, placebo-controlled Phase 3 clinical trial of atacicept in lupus nephritis. The trial will evaluate the efficacy and safety of atacicept in subjects with lupus nephritis by assessing 150 mg of once-weekly subcutaneous injections of atacicept versus placebo. The trial consists of a 52-week primary endpoint within a 104-week open-label treatment period and a 52-week safety follow-up period. Plan to announce topline data for the Phase 2b ORIGIN clinical trial - a dose-ranging study evaluating the safety and efficacy of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression - in the fourth quarter of 2022. Expect to initiate in 2023 a Phase 2b or Phase 3 clinical trial of MAU868 in BKV viremia among kidney transplant recipients.

07:33 EDT Rekor Systems to acquire Southern Traffic Services for up to $14.5M - Rekor Systems announced that it has entered into a Letter of Intent to acquire Southern Traffic Services, a company engaged in traffic engineering and advanced traffic data collection technologies across public and private agencies. Under the terms of the LOI, Rekor will acquire STS for a total purchase price of up to $14.5M, including earnouts, the amount of which will be based on the achievement of certain performance metrics. The acquisition will be funded through a combination of cash, stock, and seller notes. The closing of the transaction is subject to customary conditions and is expected to occur within the next 90 days. The acquisition will be accretive to Rekor's earnings immediately upon closing. "Southern Traffic Services has specialized in traffic data collection for over 30 years, and their in-house expertise and capabilities will bring immediate benefit to Rekor's customers," said Rekor CEO and Chairman Robert Berman. "With a well-developed network of data collection sites throughout the United States, this addition to our portfolio of products and services will help us both strengthen our technology distribution capabilities and expand Rekor's geographic footprint and customer base."

07:32 EDT Rekor Systems to acquire Southern Traffic Services for up to $14.5M

07:31 EDT Rekor Systems trading halted, news pending

07:31 EDT Chardan NexTech Acquisition 2 Corporation (Class A Stock) trading halted, news pending

07:30 EDT Aruvant announces oral presentation on ARU-1801 - Aruvant Sciences announced that data demonstrating the clinical benefit of the company's lead product candidate ARU-1801 for severe sickle cell disease will be presented today in an oral presentation at the American Society of Gene and Cell Therapy 25th annual meeting. Punam Malik, M.D., Director of the Cincinnati Comprehensive Sickle Cell Center and Program Leader of the Hematology and Gene Therapy Program at the Cincinnati Children's Hospital Medical Center, will deliver the oral presentation this afternoon at 1:30 PM EDT. Dr. Malik will be presenting data from the ongoing MOMENTUM Phase 1/2 clinical trial that is examining ARU-1801, an autologous lentiviral cell therapy with a modified, highly potent gamma globin payload, in individuals with severe SCD. ARU-1801 is designed to address the limitations of current curative allogeneic transplant options, such as low donor availability, the risk of graft-versus-host disease and toxicity from myeloablative chemotherapy. Unlike investigational gene therapies that require fully myeloablative conditioning, ARU-1801 is given with reduced intensity conditioning, which is a lower dose chemotherapy associated with less chemotherapy side effects including shorter time in the hospital and less short- and long-term toxicity than myeloablative approaches. The data being presented demonstrates: All five study participants who had sufficient follow-up have had significant reductions in severe VOEs, demonstrating clinically meaningful reductions in disease burden; Participants have experienced durable engraftment and improvement in SCD burden without the use of myeloablative chemotherapy; and Four of the five patients treated have experienced complete resolution of severe VOEs since they received the treatment.

07:28 EDT Athira Pharma presents preclinical data on ATH-1018, ATH-1019 - Athira Pharma announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve Society Annual Meeting. The research highlights the effect of ATH-1018 and ATH-1019 on neuropathic pain-related behaviors in a preclinical model of streptozotocin-induced diabetic neuropathy. Data demonstrate that measures of pain-related behaviors were significantly improved on testing days across all dose levels for each molecule. Pain-related behaviors were also significantly reduced prior to dosing on day 25 when ATH-1018 or ATH-1019 had been cleared from plasma, suggestive of potentially persistent pain-modifying effects. "Previous work has identified the HGF/MET pathway as a potential therapeutic target for peripheral neuropathies, including diabetic neuropathy, which features components of nerve damage and inflammation. Our preclinical data demonstrates the potential of ATH-1018 and ATH-1019 as therapeutic candidates for painful diabetic neuropathy," said Kevin Church, Ph.D., Executive Vice President, Research of Athira. "We look forward to the continued evaluation of these candidates to further support our pipeline expansion."

07:27 EDT scPharmaceuticals announces FDA acceptance of FUROSCIX NDA - scPharmaceuticals announced that the Company's New Drug Application, NDA, for FUROSCIX, a proprietary formulation of furosemide delivered via an on-body infusor for the treatment of congestion in patients with worsening heart failure, has been accepted for filing by the U.S. Food and Drug Administration, FDA. The FDA assigned a Prescription Drug User-Fee Act, PDUFA, target action date of October 8, 2022. "The acceptance of our FUROSCIX NDA is a significant achievement for our company and the culmination of many years of tireless work by the scPharmaceuticals team to get us to this critical point," stated John Tucker, chief executive officer of scPharmaceuticals. "We believe FUROSCIX, if approved, will address a significant need along the heart failure care continuum. By providing a new option for the treatment of congestion related to heart failure, all stakeholders - patients, payers and providers - stand to benefit, and there is the potential to generate significant healthcare system cost savings. We look forward to engaging with the FDA and continue to prepare for a successful Q4 2022 commercial launch should FUROSCIX be approved,"Tucker concluded.

07:26 EDT GXO Logistics partners with Sente Foundry to accelerate logistics innovation - GXO Logistics announced a new partnership with Sente Foundry. During the year-long collaboration, Sente will conduct a global search for and evaluation of the world's most promising technology-focused startups. The start-ups will be selected specifically for their potential to help GXO meet its strategic priorities, including accelerating warehouse innovation for customers that are increasingly looking to automate their logistics operations.

07:23 EDT Windtree Therapeutics to present data from SEISMiC Phase 2 study - Windtree Therapeutics announced management will host a conference call and webcast to discuss its istaroxime Phase 2 study in early cardiogenic shock patients following the late-breaker presentation of the data at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain on May 23, 2022. The Company previously announced a positive topline result from the trial and explained that further details were under embargo due to the acceptance of the late-breaker presentation at the Heart Failure meeting. On the call, management plans to present additional results from the study including secondary measures associated with blood pressure changes, systolic and diastolic cardiac function, renal profile, safety and tolerability. Also being presented will be next steps in development and the broader outlook for the Company.

07:22 EDT Hutchmed appoints Lefei Sun as non-executive director - HUTCHMED announces that Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he will hold office until the next annual general meeting ("AGM") of HUTCHMED when he will stand for re-election. Mr Sun has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in the healthcare and life sciences sectors. General Atlantic owns approximately 3% of the ordinary shares of HUTCHMED, through its affiliate General Atlantic Singapore HCM Pte. Ltd. Under the terms of the appointment of Mr Sun as a non-executive director of the Company until the next AGM, he has agreed that he will not receive any fee for his service and that his appointment will be renewed for successive 12-month periods, unless he is not re-elected at the next AGM or his appointment is otherwise terminated earlier by either party in writing.

07:21 EDT Ascot Resources provides outlook for 2022 activities - Management is planning a number of activities for 2022, which include: Completion of refinancing of the Senior Facility Completion of construction of the new water treatment plant and tailings storage facility in Q4 2022 Complete permanent portal brow and mine services in order to commence underground ramp development in May 2022, and advance to the delivery of ores for pre-commissioning by Q4 2022. Surface exploration drilling with a focus on the Day and Sebakwe zones Stope definition drilling at Big Missouri both from Surface and Underground Health and safety initiatives related to Covid and construction protocols Meeting a number of permitting compliance requirements as the project transitions from construction into operation Recruitment of operating personnel

07:19 EDT Kala Pharmaceuticals expects cash to fund operations into Q2 of 2023 - As of March 31, 2022, Kala had cash, cash equivalents and short-term investments of $70.2 million, compared to $92.1 million of cash and cash equivalents as of December 31, 2021. This decrease reflects cash used in operations. Based on its current plans, Kala anticipates that its cash resources as of March 31, 2022, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations into the second quarter of 2023.

07:17 EDT Bitfarms announces 2022 expansion plan update - Bitfarms' current expectations and goals for 2022 are summarized below: Existing infrastructure construction contracts are projected to provide capacity for 6.0 EH/s of miners by year-end 2022, reflecting adjustments to the Company's Argentina construction plan, and expansion opportunities in Canada and Paraguay. 2022 quarterly hashrate targets based on current infrastructure construction and miner deliveries schedules are: 4.0 EH/s as of June 30, 2022, 4.2 EH/s as of September 30, 2022, and 6.0 EH/s as of December 31, 2022. Miners and orders for miners with delivery scheduled in 2022 will be capable of producing up to 7.2 EH/s when fully operational. "Our updated development activities in Argentina, Washington, and Quebec continue on track in support of our 2022 quarterly EH/s goals," noted Geoff Morphy. "Our business development for 2022 and into 2023 are focused on a broad portfolio of opportunities, with a diversified mix in various regions where we are currently operating as well as new geographies. We are in advanced discussions for additional production facilities, all of which would utilize sustainably priced hydropower," added Morphy.

07:16 EDT Chimerix expects to initiate Phase 3 study of ONC201 in 2022 - ONC201 is an orally administered small molecule dopamine receptor D2 antagonist and caseinolytic protease agonist for the treatment of recurrent gliomas that harbor the H3 K27M mutation. The FDA had previously requested that Chimerix conduct a retrospective Natural Disease History study of recurrent H3 K27M-mutant glioma. More recently, Chimerix was informed that the FDA no longer expects to rely on the outcome of a NDH study to inform a regulatory decision given the limitations inherent in NDH studies. Therefore, the Company plans to limit further investment in this study and will disclose the findings at a later date. The Company plans to initiate a Phase 3 study of ONC201 in patients who harbor the H3 K27M-mutation. This study is designed to serve as the basis for either a confirmatory approval or first approval. Final study design and protocols are under review. Once agreement has been reached with the FDA, the Company will announce the final clinical design and timeline. While acknowledging the new regulatory sentiment with respect to single-arm data to support accelerated approval, the Company continues work to complete the safety database, clinical pharmacology studies and other items to support a possible regulatory filing for accelerated approval. In November, Chimerix reported data from the 50-patient cohort of ONC201 for the treatment of recurrent H3 K27M-mutant glioma at the Society for Neuro-Oncology Annual Meeting. According to a BICR of the registration cohort, the overall response rate was 20.0% as determined by Response Assessment in Neuro-Oncology Criteria for High Grade Gliomas. The median duration of response was 11.2 months in addition to the median time to response of 8.3 months. The proportion of patients achieving either a RANO-HGG and/or RANO-LGG response was 30%. One serious adverse event considered possibly ONC201-related by investigator was reported; however, the event was considered unlikely ONC201-related by sponsor assessment. The FDA granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant HGG, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and malignant glioma.

07:14 EDT Centessa expects cash, cash equivalents to fund operations to mid-2024 - Cash and Cash Equivalents: $544.5 million as of March 31, 2022 which the Company expects will fund operations to mid-2024, without drawing on the remaining available tranches under the Oberland credit facility.

07:12 EDT Chardan NexTech Acquisition 2 and Dragonfly to create Nasdaq-listed company - Chardan NexTech Acquisition 2 has entered into a definitive business combination agreement with Dragonfly, a provider of energy storage and producer of deep cycle lithium-ion storage batteries; upon closing, the combined company will be listed on the Nasdaq under the new ticker DFLI. Dragonfly has produced 2021 revenue and adjusted EBITDA of $78M and $8.7M, respectively, both representing an 80+% CAGR since 2018. Pro forma enterprise value of the combined company is expected to be approximately $500M. All Dragonfly shareholders will roll 100% of their equity holdings into the new combined company. Funding to support the business combination includes $128M cash from trust, a $75M senior secured term loan and a $5M equity investment from CNTQ's Sponsor. The transaction is further supported by a $150M Chardan Equity Facility - ChEFTM -. Dragonfly intends to use the proceeds from the transaction to accelerate the market penetration of its existing business and commercialize its proprietary and patented All-Solid-State-Battery technology. Dragonfly anticipates 2022 and 2023 revenue of $115M and $255M, respectively, and 2022 and 2023 adjusted EBITDA of $12M and $41M, respectively. Dragonfly Co-Founder & CEO Denis Phares and the current management team are expected to continue to lead the combined company. The transaction includes an earn-out provision for up to an additional 40 million shares. The transaction will require the approval of the stockholders of CNTQ, and is subject to satisfaction or waiver of the conditions stated in the merger agreement and other customary closing conditions, including the receipt of certain regulatory approvals. The transaction is currently expected to close in the second half of 2022.

07:10 EDT Can-Fite BioPharma granted NASH patent in Israel - Can-Fite BioPharma announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted by the Israel Patent Office. This patent has been issued in approximately 40 countries and territories including Japan, South Korea, Hong Kong, Mexico, and in the European Union. It addresses the use of the A3 Adenosine Receptor ligand, the target receptor for Can-Fite's drug platform technology, for the treatment of ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, or NASH. The treatment of NASH is a market estimated to reach $35B by 2025. Can-Fite is currently enrolling and treating patients in a Phase IIb NASH study of its liver drug candidate Namodenoson. The multi-center, randomized, double blind, and placebo controlled study of biopsy-confirmed NASH patients will measure efficacy periodically through biomarkers, with a primary efficacy endpoint determined by liver biopsy at the end of the treatment period. In a prior Phase IIa study, Namodenoson met endpoints including reduced liver fat content, anti-inflammatory effects, and decreased body weight with excellent safety.

07:08 EDT Finch Therapeutics expects cash to fund operations into 2Q24 - Finchs cash and cash equivalents as of March 31, 2022 was $106.9 million, compared to $133.5 million as of December 31, 2021. Finch believes its cash and cash equivalents on hand as of March 31, 2022, together with anticipated, non-dilutive sources of additional cash, will fund its operations into Q2 2024. These anticipated sources of cash include $15 million of funding that has now been drawn under the recent debt facility with Hercules Capital, a $10 million tranche of funding that is available at Finchs discretion under this debt facility, expected near term milestones from the Takeda partnership, and the expected subletting of one of Finchs office and lab facilities.

07:06 EDT NeoGenomics appoints Lynn Tetrault interim CEO - NeoGenomics announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022. Tetrault has been serving as Executive Chair since March when the company's CEO agreed to step down. Tetrault was overseeing the Interim Office of the CEO to provide seamless leadership continuity and operational management of the company while the Board conducts a search for the company's permanent CEO. "Lynn's leadership has been exceptional during this difficult period, and we have complete confidence in her as Interim CEO of the Company until we find the ideal candidate for the job. With Lynn serving as Interim CEO, we can streamline the management structure as we continue to execute our operational plans and create long-term value for all our shareholders. The external search for a new CEO is advancing well and is on track with our expectations," stated Michael Kelly, Lead Independent Director.

07:05 EDT Greenbrook TMS to acquire Check Five LLC - Greenbrook TMS Inc. announced that it has entered into a purchase agreement pursuant to which Greenbrook will acquire Check Five LLC, a Delaware limited liability company. Success TMS is one of the largest and fastest-growing providers of TMS therapy in the United States. Pursuant to the Purchase Agreement, Greenbrook, through its wholly-owned U.S. subsidiary, TMS NeuroHealth Centers Inc., will indirectly acquire all of the issued and outstanding equity interests in Success TMS from its parent company, Success Behavioral Holdings LLC. As consideration for the purchase of Success TMS, its direct and indirect owners, including Benjamin Klein and Batya Klein will receive, in the aggregate, approximately 11,867,923 common shares of Greenbrook. The purchase price consideration was determined based on the pro forma revenue contribution of the two companies and will be fixed at an amount equal to 40% of the total issued and outstanding common shares of Greenbrook on a post-Acquisition basis, subject to customary working capital and other adjustments. The Acquisition is an arm's length transaction and is subject to the satisfaction or waiver of customary closing conditions, including the Debt Financing and the absence of a "material adverse effect" in accordance with the terms of the Purchase Agreement, and is expected to be completed in the third quarter of 2022 with an outside date of November 15, 2022, being 6 months from the date of execution of the Purchase Agreement.

07:05 EDT Passage Bio announces anticipated upcoming milestones - Multiple presentations and posters at the ASGCT 25th Annual Meeting taking place May 16-19, 2022, including additional clinical and biomarker data from Cohort 1 of Imagine-1 and preclinical data supporting PBML04. Present interim safety and biomarker data for Cohorts 2 and 3 for Imagine-1 clinical trial for GM1 in the second half of 2022. Dose first patient in Phase 1/2 study with PBFT02 for FTD-GRN in mid-2022. Additional clinical data milestone timing to be provided following dosing of first patient. Present interim safety and biomarker data for Cohort 1 for GALax-C Phase 1/2 clinical trial for Krabbe disease by year-end 2022.

07:02 EDT GameStop names Nir Patel as COO, effective May 31 - GameStop Corp. (GME) announced it has appointed Nir Patel to the role of COO, effective May 31, 2022. Most recently, he was CEO at Belk, a privately-owned national retailer with more than 300 stores across 16 states. He previously held senior roles at Kohl's (KSS) and Lands' End (LE).

06:56 EDT Aecom awarded contract by NJ TRANSIT - Aecom announced it has been awarded a contract by NJ TRANSIT to provide engineering services for its Bus Garage Modernization Program. In this role, AECOM will design the infrastructure required for battery electric buses at NJ TRANSIT's Hilton Garage in Maplewood and conduct a survey of current conditions at 16 bus garages statewide. This work will help identify the required infrastructure upgrades needed to aid in the agency's zero-emissions transition.

06:47 EDT Warby Parker reports active customers increased 18.0% to 2.23M in Q1

06:40 EDT Wingstop announces agreement for the development rights for South Korea - Wingstop announced an agreement for the development rights for South Korea, contributing to its robust international expansion pipeline. The agreement outlines an initial commitment of 60 restaurants over a ten-year period, with the potential for 200-250 total restaurants in the country, the first expected to open in early 2023. The first of 100 planned restaurants in Canada will open next month and an expanded development agreement in Indonesia was recently executed, taking the market from 50 to 120 anticipated restaurants. Wingstop believes that it can achieve 7,000-plus global restaurants - over 3,000 of which are expected to be outside of the U.S.

06:36 EDT Similarweb acquires Rank Ranger - Similarweb acquired of Rank Ranger, a provider of SEO and rank tracking. The acquisition expands Similarweb's capabilities as a comprehensive SEO suite for enterprises by combining its keyword research and analysis capabilities with Rank Ranger's search term rank tracking. Users will be able to monitor, track and report on the rank of keywords over time across all leading search engines, now connecting how they rank for key search terms with the actual traffic those terms are driving. Rank Ranger's tools enable search professionals to monitor progress against search marketing goals, while measuring, optimizing, and reporting on the impact of specific strategies. Rank Ranger will continue to operate as Rank Ranger, a Similarweb company. Financial terms of the acquisition were not disclosed.

06:33 EDT Vivint Smart Home CFO Dale Gerard to step down, Dana Russell to succeed - Vivint Smart Home announced that Dale Gerard will be stepping down as its CFO, effective May 31st , to accept a new role with a company outside of the smart home industry. The company also announced that Dana Russell, Vivint Solar's CFO from 2013 to 2020, is joining Vivint Smart Home as its CFO and will work alongside Gerard to ensure a smooth transition. Russell will begin his tenure as chief financial officer of Vivint Smart Home immediately. He started his career as an auditor at PricewaterhouseCoopers LLP and later joined Novell, a publicly traded software and services company that was ultimately acquired by The Attachmate Group in 2011.

06:26 EDT Voyager Therapeutics to present preclinical data from anti-HER2 antibody program - Voyager Therapeutics is scheduled to present findings demonstrating preclinical proof-of-concept for its vectorized anti-HER2 antibody program and cross-species translatability for its novel AAV5-derived capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting. Preclinical data demonstrated that a single, systemic dose of a TRACER AAV9 variant, VCAP-102, encoding an anti-HER2 antibody may represent a new approach to treating brain metastases in patients with HER2+ breast cancer. In the study, Voyager's vectorized anti-HER2 antibody reduced central nervous system - CNS - tumor burden and extended survival across multiple mouse models of HER2+ brain metastases. The vectorized anti-HER2 antibody gene therapy conferred a survival benefit compared to a control antibody, with a median survival of 129 days for mice receiving the antibody versus 94 days for control mice. Also, Voyager's TRACER capsid discovery platform has identified a novel AAV5 derived variant, VCAP-100, as a strong candidate for clinical development in the delivery of gene therapies for diseases of the CNS. In the study, preclinical data demonstrated that the TRACER capsid achieved cross-species translatability through enhanced CNS transduction when administered intravenously. VCAP-100 showed 20-fold higher brain transduction and five-fold higher spinal cord transduction compared to a conventional AAV9 capsid in NHPs. No signs of toxicity were observed in histopathology of samples from macaques dosed with VCAP-100.

06:17 EDT Tanzanian Gold announces name change to TRX Gold - Tanzanian Gold is pleased to announce that it will change its name from "Tanzanian Gold Corporation" to "TRX Gold Corporation." The Name Change was approved by way of special resolution at the company's annual general and special meeting of shareholders held on February 25. The company expects the Name Change to take effect at market open on May 27. The company's common shares will continue trading on the Toronto Stock Exchange under its current ticker symbol "TNX" and on the New York Stock Exchange under its current ticker symbol "TRX". The new CUSIP of the Common Shares is 87283P109 and the new ISIN is CA87283P1099.

06:13 EDT RadNet obtains FDA clearances for DeepHeatlh Saige-DX, Quantib Prostate 2.0 - RadNet announced that it has received FDA clearances for its DeepHeatlh Saige-DX mammography and Quantib Prostate 2.0 MRI artificial intelligence algorithms.

06:10 EDT PhaseBio announces successful Pre-BLA meeting with U.S. FDA for bentracimab - PhaseBio Pharmaceuticals announced the completion of a successful Type B pre-biologics license application meeting with the U.S. FDA for bentracimab, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery. Based on this pre-BLA meeting and the formal written minutes received from the FDA, PhaseBio intends to submit the BLA for bentracimab by early in the fourth quarter of 2022. During the pre-BLA meeting, the FDA agreed that the company's plans to submit a BLA with data from 25-30 patients with uncontrolled bleeding, together with data from the fully completed surgical cohort, appeared reasonable to support a label with both bleeding and surgical indications but would be a review issue based on the data submitted. To date, and subject to final adjudication, the REVERSE-IT trial has enrolled 35 patients taking ticagrelor who experienced uncontrolled bleeding events. PhaseBio previously intended to base its BLA submission on data from the interim analysis of the Phase 3 REVERSE-IT trial published in December 2021, and the recently presented Phase 2b trial data. Based on the feedback received from the FDA during the pre-BLA meeting, PhaseBio will include in the BLA submission the additional bleeding patients who have enrolled in the REVERSE-IT trial since the pre-specified interim analysis was completed to support a potential bleeding indication.

06:06 EDT Photronics names Dr. Frank Lee as CEO - Photronics announced that Dr. Frank Lee, who was named President on March 14, has been named CEO and will join the company's Board of Directors. Constantine Macricostas, who in addition to his role as Chairman of the Board had also been serving as interim CEO. He will continue to serve as Chairman. The company also announced today that Adam Lewis is joining its Board of Directors as an independent director. Adam has over 20 years of experience in financial advisory to technology companies with a focus on digital infrastructure and cyber security. Dr. Lee's career includes roles at Fairchild Semiconductor, Intel and Soliconix. He was Vice President of Operations of Texas Instruments-Acer in Taiwan and held leadership positions with TSMC-Acer in Taiwan, and UMC in Taiwan. Prior to joining Photronics in 2006, he was CEO of NSMC.

06:05 EDT Renault confirms financial outlook as announced on March 23

06:04 EDT Seagen CEO Clay Siegall resigns, Roger Dansey to continue as interim CEO - Seagen announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors to undertake, with the assistance of an independent law firm, a thorough investigation into Dr. Siegall's conduct. While the investigation continues, the Board and Dr. Siegall agreed it is in the best interests of Seagen and its stakeholders for him to resign at this time. Dr. Siegall's resignation has not been driven by findings from the investigation. The Board is commencing a search for a permanent CEO.

06:02 EDT Diamondback Energy to acquire publicly held units of Rattler Midstream - Diamondback Energy (FANG) and Rattler Midstream LP (RTLR) announced that, on May 15, they entered into a definitive agreement for Diamondback to acquire all of the publicly held common units representing the limited partner interests in Rattler not already owned by Diamondback and its subsidiaries. The agreement provides for an all-stock transaction whereby each public unitholder of Rattler would receive 0.113 of a share of common stock in Diamondback in exchange for each Rattler common unit owned, an exchange ratio that implies a premium of 17.3% for Rattler common units based on the closing prices of Rattler's common units and Diamondback's common stock as of May 13, and a premium of 9.3% based on Rattler's and Diamondback's 30 day volume-weighted average trading price as of the same date. The Conflicts Committee of the board of directors of Rattler's general partner, composed of independent directors, unanimously approved the merger agreement after consultation with its independent legal and financial advisors. The merger agreement was subsequently unanimously approved by the board of directors of Rattler's general partner. Diamondback E&P LLC, a wholly owned subsidiary of Diamondback and the holder of a majority of the outstanding units of Rattler, has voted its units to approve the transaction. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions.

05:26 EDT Nutex Health announces two new micro hospitals - Nutex Health announced two new fully operational micro hospitals. The first hospital, New Braunfels ER & Hospital, is in New Braunfels, Texas, located about 30 miles northeast of San Antonio. The facility is open 24/7, 365 days a year, and includes an emergency room with nine private exam rooms staffed with board-certified physicians and four private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including CT, X-Ray and ultrasound with rapid radiological reports. The second hospital, East Valley ER & Hospital, is in Gilbert, Arizona, located about 21 miles southeast of Phoenix. The hospital is open 24/7, 365 days a year, and includes an emergency room with 14 private exam rooms and 14 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including MRI, CT, X-Ray and ultrasound. Nutex currently anticipates opening three more facilities in 2022, with another 17 facilities either under construction or in advanced planning stages and anticipated to open in 2023 and 2024. There can be no assurance that these additional facilities will open in the anticipated timing or that they will open at all.

05:18 EDT Sempra Energy subsidiary enters 20-year HOA with PGNiG - Sempra Infrastructure, a subsidiary of Sempra Energy, and the Polish Oil & Gas Company, or PGNiG, announced they have entered into a heads of agreement, or HOA, for the purchase of approximately 3M tons per annum, or Mtpa, of liquefied natural gas, or LNG, delivered free-on-board from Sempra Infrastructure's portfolio of LNG projects in North America. The referenced HOA contemplates the negotiation and finalization of definitive 20-year LNG sale-and-purchase agreements for 2 Mtpa from the Cameron LNG Phase 2 project under development in Louisiana, and 1 Mtpa from the Port Arthur LNG project under development in Texas. The HOA also provides PGNiG the opportunity in 2022 to reallocate volumes from the Cameron LNG Phase 2 project to the Port Arthur LNG project. Additionally, Sempra Infrastructure and PGNiG expect to continue working toward a framework for the reduction, mitigation and reporting of greenhouse gas emissions across the LNG value chain.